Zomedica (ZOM) 10-K 26 Feb 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	Zomedica Corp.
Entity Central Index Key	0001684144
Trading Symbol	zom
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		947,298,207
Entity Public Float			$ 82.4
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common Shares, without par value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 61,991,703	$ 510,586
Prepaid expenses and deposits	727,814	1,228,585
Tax credits receivable	146,207	67,618
Assets, Current, Total	62,865,724	1,806,789
Prepaid Expenses and Deposits, Noncurrent	1,000,000	0
Property and equipment	583,007	729,142
Right-of-use asset	1,318,716	1,103,658
Intangible assets	376,587	543,395
Assets, Total	66,144,034	4,182,984
Current liabilities:
Accounts payable and accrued liabilities	1,248,628	2,087,525
Current portion of debt obligation	527,360
Current portion of lease liabilities	252,788
Liabilities, Current, Total	2,028,776	2,087,525
Lease obligations	1,087,998
Liabilities, Total	3,116,774	2,087,525
Shareholders' equity:
Series 1 preferred shares, without par value; 20 shares authorized (2019 - 20) 12 series 1 Issued and outstanding (2019 - 12)		11,961,397
Unlimited common shares without par value; Issued and outstanding 642,036,228 common shares (2019 - 108,308,398)	104,783,612	38,566,820
Common stock subscribed	459,600
Additional paid-in capital	14,792,276	3,625,083
Accumulated deficit	(68,969,625)	(52,057,841)
Stockholders' Equity Attributable to Parent, Ending Balance	51,065,863	2,095,459
Liabilities and Equity, Total	66,144,034	4,182,984
Series 1 Preferred Shares [Member]
Mezzanine equity:
Series 1 preferred shares, without par value; 20 shares authorized (2019 - 20) 12 series 1 Issued and outstanding (2019 - 12)	11,961,397
Shareholders' equity:
Series 1 preferred shares, without par value; 20 shares authorized (2019 - 20) 12 series 1 Issued and outstanding (2019 - 12)	$ 11,961,397	$ 11,961,397

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, authorized (in shares)	20	20
Preferred stock, issued (in shares)	12	12
Preferred stock, outstanding (in shares)	12	12
Capital stock, unlimited common shares	Unlimited	Unlimited
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, issued (in shares)	642,036,228	108,038,398
Capital stock, outstanding (in shares)	642,036,228	108,038,398
Series 1 Preferred Shares [Member]
Mezzanine equity, par value (in dollars per share)	$ 0	$ 0
Mezzanine equity, shares authorized (in shares)	20	20
Mezzanine equity, shares issued (in shares)	12	12
Mezzanine equity, shares outstanding (in shares)	12	12
Preferred stock, authorized (in shares)	20
Preferred stock, issued (in shares)	12	12

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Expenses:
Research and development	$ 8,043,891	$ 10,345,291
General and administrative	6,011,985	6,985,334
Professional fees	2,179,082	1,666,089
Amortization - intangible asset	181,658	1,082
Amortization - right-of-use asset	42,448	509,381
Depreciation	305,914	277,150
Loss from operations	16,764,978	19,784,327
Interest income	(32,859)
Interest expense	732	18,338
Loss on disposal of property and equipment	121,034	1,308
Operating Lease, Impairment Loss	59,097
Gain on settlement of liabilities		(19,737)
Other income (expense)	(8,601)
Foreign exchange gain	7,403	(182)
Loss before income taxes	16,911,784	19,784,054
Income tax expense
Net loss and comprehensive loss	$ 16,911,784	$ 19,784,054
Weighted average number of common shares - basic and diluted (in shares)	364,444,664	106,297,975
Loss per share - basic and diluted (in dollars per share)	$ (0.05)	$ (0.19)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($)		Preferred Stock [Member]	Common Stock [Member]		Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018			97,598,898
Balance at Dec. 31, 2018			$ 30,410,648		$ 4,280,000	$ 1,240,139	$ (32,273,787)	$ 3,657,000
Stock issuance for services (in shares)			707,236	[1],[2]
Stock issuance for services			$ 792,104	[1],[2]				792,104
Stock issuance for financing, net of cost (in shares)		12	9,337,529	[3],[4]
Stock issuance for financing, net of cost		$ 11,961,397	$ 6,609,920	[3],[4]	(4,280,000)			14,291,317
Stock-based compensation						2,539,092		$ 2,539,092
Stock issuance due to exercise of options (in shares)			394,735					394,735
Stock issuance due to exercise of options			$ 754,148			(154,148)		$ 600,000
Net loss							(19,784,054)	(19,784,054)
Balance (in shares) at Dec. 31, 2019		12	108,038,398
Balance at Dec. 31, 2019		$ 11,961,397	$ 38,566,820			3,625,083	(52,057,841)	2,095,459
Stock issuance for services (in shares)			337,830,001
Stock issuance for services			$ 32,275,265			24,221,018		56,496,283
Stock issuance for financing, net of cost (in shares)	[5],[6],[7],[8]		337,830,001
Stock issuance for financing, net of cost	[5],[6],[7],[8]		$ 29,295,671
Stock-based compensation						1,656,184		$ 1,656,184
Stock issuance due to exercise of options (in shares)								0
Net loss							(16,911,784)	$ (16,911,784)
Stock issuance costs			(2,979,594)			(2,128,022)		(5,107,616)
Placement agent warrants			$ (154,767)			154,767
Stock issued due to exercise of warrants and prefunded warrants (in shares)			196,167,829
Stock issued due to exercise of warrants and prefunded warrants			$ 37,075,888			(12,736,754)		24,339,134
Common stock subscribed					459,600			459,600
Reclassification to mezzanine equity (in shares)		(12)
Reclassification to mezzanine equity		$ (11,961,397)						(11,961,397)
Balance (in shares) at Dec. 31, 2020			642,036,228
Balance at Dec. 31, 2020			$ 104,783,612		$ 459,600	$ 14,792,276	$ (68,969,625)	$ 51,065,863
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance.
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities in the consolidated statement of loss and comprehensive loss;
[3]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018.The Company recorded $465 of share issuance costs as an offset to common stock;
[4]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded $669,615 of share issuance costs as an offset to common stock in the year ended December 31, 2019.
[5]	On April 9, 2020 the Company completed a confidentially marketed public offering ("CMPO") of its common shares and warrants ("Series B Warrants") of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares. The securities were sold in a fixed combination of one common share and 0.5 of a Series B Warrant at a combined offering price of $0.12 per share and accompanying warrant. Each whole warrant is exercisable immediately for one common share after issuance, at an exercise price of $0.15 per share and has a term of 5 years. The Company also issued warrants to the placement agents to purchase 1,666,667 common shares at an exercise price of $0.15 per share ("Series B Placement Agent Warrants"), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 33,333,334 common shares, 16,666,667 Series B Warrants, and an additional 1,666,667 Series B Placement Agent Warrants. The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders' equity using the relative fair value approach. The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares and warrants issued in April were $582,977. These direct costs were recorded as an offset against the statement of shareholders' equity with $428,283 being recorded under capital stock and $154,694 being recorded under additional paid-in-capital. The Company also recorded the value of the Series B Placement Agent Warrants in the amount of $161,714 as an offset against the statement of shareholders' equity, with $118,951 being recorded under capital stock and $42,763 being recorded under additional paid-in-capital.
[6]	On February 14, 2020, the Company completed a registered direct offering ("RDO") of its common shares and a simultaneous private placement of its warrants ("Series A Warrants") in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5- and one-half years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share ("Series A Placement Agent Warrants"), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants, and an additional 1,041,667 Series A Placement Agent Warrants. The Company raised $2,500,000 in gross proceeds as part of the RDO. The Company recorded $1,705,655 as the value of common shares under common stock and $794,345 as the value of Series A Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 were $348,220. These direct costs were recorded as an offset against the statement of shareholders' equity with $238,217 being recorded under capital stock and $110,003 being recorded under additional paid-in-capital. The Company also recorded the value of the Series A Placement Agent Warrants in the amount of $52,496 as an offset against the statement of shareholders' equity with $35,816 being recorded under capital stock and $16,680 being recorded under additional paid-in-capital.
[7]	On July 7, 2020 the Company completed a public offering of its common shares or common share equivalents ("Series D Pre-Funded Warrants"), and warrants ("Series D Warrants") in a fixed combination of one common share or Series D Pre-Funded warrant, and a Series D Warrant to purchase one common share, resulting in the sale of 162,500,000 common shares, 25,000,000 Series D Pre-Funded Warrants, and Series D Warrants to purchase 187,500,000 common shares at a combined offering price of $0.16 per share for the common shares and related Series D Warrant, or a combined offering price of $0.1599 per Series D Pre-Funded Warrant and related Series D Warrant. Each Series D Pre-Funded Warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series D Warrant has an exercise price of $0.16 per share, is exercisable immediately after issuance, and has a term of 2 years. The Company raised $29,997,500 in gross proceeds as part of the public offering. The Company recorded $16,290,941 as the value of common shares under common stock, $2,329,983 as the value of the Series D Pre-Funded Warrants and $11,376,575 as the value of the Series D Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders' equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares, Series D Pre-Funded Warrants and Series D Warrants issued in July 2020 were $2,268,215. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,224,218 being recorded under capital stock and $1,043,997 being recorded under additional paid-in-capital. The Company raised $29,997,500 in gross proceeds as part of the public offering. The Company recorded $16,290,941 as the value of common shares under common stock, $2,329,983 as the value of the Series D Pre-Funded Warrants and $11,376,575 as the value of the Series D Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares, Series D Pre-Funded Warrants and Series D Warrants issued in July 2020 were $2,268,215. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,224,218 being recorded under capital stock and $1,043,997 being recorded under additional paid-in-capital.
[8]	On May 29, 2020 the Company completed a public offering of its common shares or common share equivalents ("Series C Pre-Funded Warrants"), and warrants ("Series C Warrants") in a fixed combination of one common share or Series C Pre-Funded Warrant, and a Series C Warrant to purchase one common share, resulting in the sale of 121,163,333 common shares, 12,170,000 Series C Pre-Funded Warrants, and Series C Warrants to purchase 133,333,333 common shares at a combined offering price of $0.15 per share for the common shares and related Series C Warrant, or a combined offering price of $0.1499 per Series C Pre-Funded Warrant and related Series C Warrant. Each Series C Pre-Funded Warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series C Warrant has an exercise price of $0.15 per share, is exercisable immediately after issuance and has a term of 2 years. The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the Series C Pre-Funded Warrants and $7,582,072 as the value of Series C Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders' equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares, Series C Pre-Funded Warrants and Series C Warrants issued in May 2020 were $1,908,202. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,088,876 being recorded under capital stock and $819,327 being recorded under additional paid-in-capital. The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the Series C Pre-Funded Warrants and $7,582,072 as the value of Series C Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares, Series C Pre-Funded Warrants and Series C Warrants issued in May 2020 were $1,908,202. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,088,876 being recorded under capital stock and $819,327 being recorded under additional paid-in-capital.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows used in operating activities:
Net loss	$ (16,911,784)	$ (19,784,054)
Adjustments for
Depreciation	(305,914)	(277,150)
Amortization - intangible assets	181,658	1,082
Amortization - right-of-use asset	42,448	509,381
Loss on sale of property and equipment	121,034	1,308
Loss on right-of-use assets	59,097
Non cash portion of rent expense	22,069
Stock issued for services		792,104
Stock-based compensation	1,656,184	2,539,092
Change in non-cash operating working capital
Trade and other receivable	(78,589)	(13,959)
Prepaid expenses	(77,341)	239,953
Deposits	(721,156)	92,873
Accounts payable and accrued liabilities	(838,897)	(288,994)
Net Cash Provided by (Used in) Operating Activities, Total	(16,239,363)	(15,634,064)
Cash flows from financing activities:
Cash proceeds from issuance of preferred shares		12,000,000
Cash proceeds from issuance of common shares, warrants and pre-funded warrants	56,496,283	3,000,000
Cash received from warrant exercises	24,339,134	600,000
Cash paid on stock and warrant issuance costs	(5,107,616)	(708,683)
Cash from common stock subscribed	459,600
Cash received from debt obligation	527,360
Net Cash Provided by (Used in) Financing Activities, Total	76,714,761	14,891,317
Cash flows from (used) in investing activities:
Cash received from sale of property and equipment	20,400	0
Investment in intangibles	(1,944)	(531,419)
Investment in property and equipment	(14,850)	(155,513)
Cash from lease repurchase	1,002,113
Net Cash Provided by (Used in) Investing Activities, Total	1,005,719	(686,932)
Increase (Decrease) in cash and cash equivalents	61,481,117	(1,429,679)
Cash and cash equivalents, beginning of year	510,586	1,940,265
Cash and cash equivalents, end of year	61,991,703	510,586
Supplemental cash flow information:
Interest paid	732	18,338
Interest (received)	$ (32,353)

Note 1 - Nature of Operations

Note 1 - Nature of Operations	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	1. Nature of operations Zomedica Corp. ("Zomedica" or the “Company”) was incorporated on January 7, 2013 Business Corporations Act 2.4 May 14, 2015 On April 21, 2016, three 9674128 one 2.5 2.4 Capital Pool Companies May 2, 2016. June 21, 2016, November 17, 2017, February 10, 2020, October 5, 2020, Zomedica has one 100 180, 48108 3400, 350 7 th T2P 3N9. January 19, 2021,

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of preparation The accounting policies set out below have been applied consistently in the consolidated financial statements. The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Basis of consolidation These consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc. All inter-company accounts and transactions have been eliminated on consolidation.

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant accounting policies Use of estimates The preparation of the consolidated financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are the determination of fair value of stock-based compensation, the useful lives of property and equipment, allocation of proceeds from financings to shares and warrants, and fair value of placement agent warrants. Basis of measurement The consolidated financial statements have been prepared on the historical cost basis except as otherwise noted. Functional and reporting currencies The Company's and subsidiary's functional currency, as determined by management, is US dollars, which is also the Company's reporting currency. Cash and cash equivalents The Company considers all highly liquid securities with an original maturity of three The financial risks associated with these instruments are minimal and the Company has not Property and equipment Property and equipment are carried at historical cost less accumulated depreciation and any accumulated impairment losses. Maintenance and repair expenditures that do not Depreciation is recognized so as to write off the cost less their residual values over their useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. An item of property and equipment is derecognized upon disposal or when no Estimated useful lives for the principal asset categories are as follows: Computer equipment (years) 3 Furniture and equipment (years) 5 - 7 Laboratory equipment (years) 5 - 7 Leasehold improvements Over shorter of estimated useful life and lease term Impairment of long-lived assets Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Translation of foreign currencies In respect of transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries' functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are measured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations and comprehensive loss. Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during fiscal 2020 2019 not December 31, 2020 2019 Comprehensive loss The Company follows ASC topic 220. no Intangible assets Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses. Computer software and website (years) 3 Trademarks (years) 15 Fair value measurement Under ASC topic 820, 820 three l Level 1 l Level 2 1 2 not l Level 3 The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Income taxes The Company accounts for income taxes in accordance with Accounting Standard Codification 740, 740" Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not not The Company assesses the likelihood of the financial statement effect of an uncertain tax position that should be recognized when it is more likely than not not ASC 740 740 December 31, 2020 2019, not 740. Segmented reporting The Company currently operates as a single segment. Its principal business relates to the discovery, development and commercialization of innovative pharmaceuticals for the companion pet.

Note 4 - Critical Accounting Ju

Note 4 - Critical Accounting Judgments and Key Sources of Estimation Uncertainty	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Critical Accounting Judgments and Key Sources of Estimation Uncertainly [Text Block]	4. Critical accounting judgments and key sources of estimation uncertainty The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not may The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Critical areas of estimation and judgements in applying accounting policies include the following: Stock-based payments The Company estimates the fair value of convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around assumptions and inputs such as expected term to maturity, volatility and dividends. Useful lives of property and equipment The Company reviews the estimated useful lives of property and equipment with definite useful lives at the end of each year and assesses whether the useful lives of certain items should be shortened or extended due to various factors including technology, competition and revised service offerings. During the year ended December 31, 2020 2019, not may not The impact of the novel strain of coronavirus (“COVID- 19” The outbreak of the novel strain of coronavirus, specifically identified as “COVID- 19”, March 2020. The COVID- 19 five five may 19 may 19, Accounting for preferred shares The Company analyzes preferred shares upon issuance for any conditions or clauses that require derivative classification and bifurcation in accordance with U.S GAAP. The Company also considers any change of control clauses within the agreement and whether they are in the control of management and the Company in order to conclude on equity classification or mezzanine equity classification. This analysis requires significant judgement. Accounting for equity placements The Company values warrants issued in equity placements using the Black Scholes model in order to allocate the fair value of the proceeds from equity financings using a relative fair value approach. Similar to other stock-based compensation, management uses judgment to determine the inputs to the Black-Scholes option pricing model including the expected life, and underlying share price volatility. Changes in these assumptions will impact the calculation of fair value and the value attributed to the warrants.

Note 5 - Prepaid Expenses, Depo

Note 5 - Prepaid Expenses, Deposits and Deferred Financing Costs	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Prepaid Rent [Text Block]	5. Prepaid expenses, deposits and deferred financing costs December 31, December 31, 2020 2019 Deposits (i) 1,455,119 1,033,231 Prepaid marketing (ii) 26,330 19,829 Prepaid insurance (ii) 184,154 110,636 Other (iii) 62,211 64,889 Total $ 1,727,814 $ 1,228,585 (i) Deposits include payments made to vendors in advance and are primarily associated with, research activity, leasing deposits and costs for additional office space. As of December 31, 2020, December 31, 2019, $1,000,000 nil (ii) As of December 31, 2020, December 31, 2019, (iii) Other is comprised of deferred financing costs, subscription payments, utilities, travel costs and software licensing. As of December 31, 2020, December 31, 2019,

Note 6 - Property and Equipment

Note 6 - Property and Equipment	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2018 $ 170,002 $ 181,879 $ 352,637 $ 282,975 $ 987,493 Additions 218,076 3,415 3,350 65,672 290,513 Disposals (2,210 ) - - - (2,210 ) Balance at December 31, 2019 385,868 185,294 355,987 348,647 1,275,796 Additions 1,944 - - 299,268 301,212 Disposals (23,648 ) (64,013 ) (121,900 ) (76,455 ) (286,016 ) Balance at December 31, 2020 364,165 121,281 234,087 571,460 1,290,993 Accumulated depreciation Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 88,417 26,617 68,519 93,597 277,150 Disposals (901 ) - - - (901 ) Balance at December 31, 2019 192,434 56,202 168,215 129,803 546,654 Depreciation 86,382 18,588 65,668 135,276 305,914 Disposals (22,370 ) (29,279 ) (55,702 ) (37,231 ) (144,582 ) Balance at December 31, 2020 256,446 45,511 178,181 227,848 707,986 Net book value as at: December 31, 2019 $ 193,434 $ 129,092 $ 187,772 $ 218,844 $ 729,142 December 31, 2020 $ 107,719 $ 75,770 $ 55,906 $ 343,612 $ 583,007 For the years ended December 31, 2020 2019, $141,434 $1,308. $20,400 nil $121,034 $1,308 December 31, 2020 2019. In February 2020, $299,268 February 2020 2019.

Note 7 - Intangible Assets

Note 7 - Intangible Assets	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. Intangible assets Computer software Trademarks Website Warranty Total intangible assets Cost Balance at December 31, 2018 22,882 16,236 - - 21,379 Additions - - 513,680 - 531,419 Balance at December 31, 2019 22,882 16,236 513,680 - 552,798 Additions - - - 14,850 14,850 Balance at December 31, 2020 22,882 16,236 513,680 14,850 567,648 Accumulated amortization Balance at December 31, 2018 5,143 3,178 - - 8,321 Amortization - 1,082 - - 1,082 Balance at December 31, 2019 5,143 4,260 - - 9,403 Amortization 5,996 1,095 173,641 926 181,658 Balance at December 31, 2020 11,139 5,355 173,641 926 191,061 Net book value as at: December 31, 2019 $ 17,739 $ 11,976 $ 513,680 - $ 543,395 December 31, 2020 $ 11,743 $ 10,881 $ 340,039 $ 13,924 $ 376,587 The estimated future amortization of intangible is as follows: 2021 $ 184,139 2022 176,832 2023 1,076 2024 1,076 2025 1,076 Total $ 364,199

Note 8 - Leases

Note 8 - Leases	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases The Company adopted ASC 842 January 1, 2019. two January 1, 2019, $1,613,039 $42,448 $509,381 December 31, 2020 December 31, 2019. On February 1, 2020 60 February 1, 2020 January 31, 2025 $32,452, $36,525 $1,002,113. $1,061,210 February 2020, $59,097 On February 1, 2020, $1,553,611 12%. December 31, 2020, December 31, 2019, $379,041 nil $83,425 nil $295,616 nil December 31, 2020, December 31, 2019, $4,331 $32,473 Right-of-use asset Premise lease Cost Aggregate lease commitments $ 2,067,505 Less: impact of present value (513,894 ) Balance at December 31, 2020 1,553,611 Reduction in right-of-use asset Straight line amortization 379,043 Interest (144,148 ) Balance at December 31, 2020 234,895 Net book value as of: December 31, 2020 $ 1,318,716 Lease liabilities Premise lease Additions $ 1,553,611 Payments (356,972 ) Interest 144,147 Total lease liabilities at December 31, 2020 1,340,786 Current portion of lease liabilities 252,788 Long term portion of lease liabilities 1,087,998 Total lease liabilities at December 31, 2020 $ 1,340,786 Total remaining undiscounted lease liabilities related to the above lease are as follows: 2021 400,133 2022 412,137 2023 424,501 2024 437,236 2025 36,526 Total $ 1,710,533

Note 9 - Loan Arrangements

Note 9 - Loan Arrangements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	9. Loan Arrangements On October 18, 2017, may $5,000,000, five 5 may one $250,000 one not two may fourteen 14% December 31, 2020, no During the year ended December 31, 2020, $527,360 two 1%

Note 10 - Preferred Stock

Note 10 - Preferred Stock	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred stock The Company is authorized to issue up to 20 1 $1,000,000. 1 not not 1 not 9 9 1 1 9 1 Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 1 1 In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which our shareholders do not 50% may third 1 1 1 5.0 9.0 Due to financings completed during the year ended December 31, 2020, not Issued and outstanding preferred stock: Number of Preferred preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing 12 $ 11,961,397 Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 $ 11,961,397

Note 11 - Common Stock

Note 11 - Common Stock	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common stock The Company is authorized to issue an unlimited number of common shares, all without par value. Issued and outstanding common stock: Number of common Common stock stock amount Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issuance for services (i and ii) 707,236 792,104 Stock issued from financing (iii and iv) 9,337,529 6,609,920 Stock issued due to exercise of options 394,735 754,148 Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (v,vi,vii,viii) 337,830,001 29,295,671 Stock issued from the financing and exercise of prefunded warrants (vii and viii) 37,146,984 12,581,987 Stock issued from the exercise of warrants (ix, x, xi) 159,020,845 24,339,134 Balance at December 31, 2020 642,036,228 $ 104,783,612 i) On January 14, 2019, $75,000 49,342 $55,263 $19,737 ii) On January 14, 2019, 657,894 $1,000,000 third $736,841 iii) On January 14, 2019, 2,815,789 $4,280,000 December 31, 2018.The $465 iv) On March 28, 2019, 6,521,740 $3,000,000. $669,615 December 31, 2019. v) On February 14, 2020, one one 20,833,334 20,833,334 $0.12 $0.20 six 5 one 1,041,667 $0.15 5 20,833,334 20,833,334 1,041,667 The Company raised $2,500,000 $1,705,655 $794,345 13 The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 $348,220. $238,217 $110,003 $52,496 $35,816 $16,680 (vi) On April 9, 2020 33,333,334 16,666,667 one 0.5 $0.12 one $0.15 5 1,666,667 $0.15 5 33,333,334 16,666,667 1,666,667 The Company raised $4,000,000 $2,942,248 $1,057,752 13 The direct cash costs related to the issuance of the common shares and warrants issued in April $582,977. $428,283 $154,694 $161,714 $118,951 $42,763 (vii) On May 29, 2020 one one 121,163,333 12,170,000 133,333,333 $0.15 $0.1499 $0.0001 not $0.15 2 The Company raised $19,998,783 $11,336,422 $1,080,289 $7,582,072 13 The direct cash costs related to the issuance of the common shares, Series C Pre-Funded Warrants and Series C Warrants issued in May 2020 $1,908,202. $1,088,876 $819,327 (viii) On July 7, 2020 one one 162,500,000 25,000,000 187,500,000 $0.16 $0.1599 $0.0001 not $0.16 2 The Company raised $29,997,500 $16,290,941 $2,329,983 $11,376,575 13 The direct cash costs related to the issuance of the common shares, Series D Pre-Funded Warrants and Series D Warrants issued in July 2020 $2,268,215. $1,224,218 $1,043,997 (ix) All Series C Pre-Funded Warrants were exercised in June 2020. 12,162,492 ( x All Series D Pre-Funded Warrants were exercised in July 2020. 24,984,492 (xi) During the year ended December 31, 2020, 14,929,582 $2,237,437, 95,490,638 $14,323,596, 48,600,625 $7,776,101.

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock-based compensation During the years ended December 31, 2020, December 31, 2019, nil 394,735 December 31, 2020, December 31, 2019, 35,471,000 7,495,000 one The continuity of stock options are as follows: Number of options Weighted avg exercise price Balance at December 31, 2018 422,044 1.95 Stock options granted January 10, 2019 5,995,000 1.52 Stock options expired February 24, 2019 (35,000 ) 1.15 Stock options exercised March 8, 2019 (164,473 ) 1.52 Stock options exercised March 15, 2019 (164,473 ) 1.52 Stock options exercised March 29, 2019 (65,789 ) 1.52 Stock options expired May 23, 2019 (10,000 ) 1.52 Stock options expired June 16, 2019 (40,000 ) 1.52 Stock options cancelled July 14, 2019 (5,000 ) 1.52 Stock options cancelled August 13, 2019 (5,000 ) 1.52 Stock options expired August 14, 2019 (387,004 ) 2.11 Stock options granted August 19, 2019 500,000 0.26 Stock options granted August 19, 2019 100,000 0.35 Stock options granted August 19, 2019 100,000 0.45 Stock options granted August 19, 2019 100,000 0.55 Stock options granted August 19, 2019 100,000 0.65 Stock options granted August 19, 2019 100,000 0.75 Stock options granted September 16, 2019 500,000 0.43 Balance at December 31, 2019 7,040,265 $ 1.28 Stock options forfeited January 23, 2020 (50,000 ) 1.52 Stock options forfeited February 25, 2020 (5,000 ) 1.12 Stock options forfeited March 1, 2020 (50,000 ) 1.52 Stock options granted March 14, 2020 5,056,000 0.19 Stock options forfeited April 21, 2020 (150,000 ) 0.19 Stock options forfeited May 4, 2019 (15,000 ) 0.19 Stock options forfeited May 5, 2020 (30,000 ) 1.52 Stock options forfeited May 7, 2020 (15,000 ) 1.52 Stock options forfeited June 11, 2020 (15,000 ) 1.52 Stock options granted June 16, 2020 2,000,000 0.19 Stock options granted July 9, 2020 175,000 0.18 Stock options forfeited July 20, 2020 (400,000 ) 1.52 Stock options forfeited July 20, 2020 (50,000 ) 0.19 Stock options forfeited July 31, 2020 (3,750 ) 0.19 Stock options forfeited August 2, 2020 (10,000 ) 1.52 Stock options forfeited August 2, 2020 (5,000 ) 0.19 Stock options forfeited August 14, 2020 (675,000 ) 0.19 Stock options forfeited August 19, 2020 (75,375 ) 0.19 Stock options granted August 25, 2020 40,000 0.13 Stock options forfeited September 25, 2020 (37,500 ) 0.19 Stock options granted September 29, 2020 300,000 0.11 Stock options granted October 1, 2020 300,000 0.11 Stock options forfeited October 15, 2020 (56,250 ) 0.19 Stock options granted October 20, 2020 40,000 0.09 Stock options forfeited October 29, 2020 (1,250 ) 0.19 Stock options forfeited November 12, 2020 (225,000 ) 0.19 Stock options forfeited November 12, 2020 (950,000 ) 1.52 Stock options forfeited November 17, 2020 (25,125 ) 0.19 Stock options forfeited November 17, 2020 (50,000 ) 1.52 Stock options forfeited December 24, 2020 (12,500 ) 0.19 Stock options granted December 31, 2020 27,560,000 0.23 Balance at December 31, 2020 39,604,515 $ 0.36 Vested at December 31, 2020 14,624,140 $ 0.59 As at December 31, 2019, Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) January 10, 2019 $ 1.52 5,540,265 5,540,265 - 1.03 August 19, 2019 0.26 500,000 500,000 - 1.64 August 19, 2019 0.35 100,000 100,000 - 1.64 August 19, 2019 0.45 100,000 100,000 - 1.64 August 19, 2019 0.55 100,000 100,000 - 1.64 August 19, 2019 0.65 100,000 100,000 - 1.64 August 19, 2019 0.75 100,000 100,000 - 1.64 September 16, 2019 0.43 500,000 500,000 - 1.71 Balance at December 31, 2019 7,040,265 7,040,265 - As at December 31, 2020, Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) January 10, 2019 1.52 3,965,265 3,965,265 - 0.03 August 19, 2019 0.26 500,000 500,000 - 0.63 August 19, 2019 0.35 100,000 100,000 - 0.63 August 19, 2019 0.45 100,000 100,000 - 0.63 August 19, 2019 0.55 100,000 100,000 - 0.63 August 19, 2019 0.65 100,000 100,000 - 0.63 August 19, 2019 0.75 100,000 100,000 - 0.63 September 16, 2019 0.43 500,000 500,000 - 0.71 March 14, 2020 0.19 3,724,250 945,125 2,779,125 4.20 June 16, 2020 0.19 2,000,000 2,000,000 - 4.46 July 9, 2020 0.18 175,000 43,750 131,250 4.52 August 25, 2020 0.13 40,000 10,000 30,000 4.65 September 29, 2020 0.11 300,000 75,000 225,000 4.75 October 1, 2020 0.11 300,000 75,000 225,000 4.75 October 20, 2020 0.09 40,000 10,000 30,000 4.81 December 31, 2020 0.23 27,560,000 6,000,000 21,560,000 10.00 Balance at December 31, 2020 39,604,515 14,624,140 24,980,375 The Company granted 35,471,000 December 31, 2020 ( December 31, 2019 – 7,495,000 December 31, 2020 2019 July 9, 2020 June 16, 2020 March 14, 2020 Volatility 100% 100% 87% Risk-free interest rate 0.28% 0.21% 0.49% Expected life (years) 5 5 5 Divedend yield 0% 0% 0% Common share price $0.17 $0.19 $0.18 Strike price $0.18 $0.19 $0.19 Forfeiture rate nil nil nil October 1, 2020 September 29, 2020 August 25, 2020 Volatility 100% 100% 99% Risk-free interest rate 0.27% 0.24% 0.30% Expected life (years) 5 5 5 Dividend yield 0% 0% 0% Common share price $0.10 $0.10 $0.13 Strike price $0.11 $0.11 $0.13 Forfeiture rate nil nil nil December 31, 2020 October 20, 2020 Volatility 102% 100% Risk-free interest rate 0.51% 0.34% Expected life (years) 5.75 5 Dividend yield 0% 0% Common share price $0.23 $0.08 Strike price $0.23 $0.09 Forfeiture rate nil nil January 10, 2019 August 19, 2019 September 16, 2019 Volatility 68% 87% 89% Risk-free interest rate 2.56% 1.48% 1.74% Expected life (years) 2 2 2 Dividend yield 0 0 0 Common share price $1.23 $0.26 $0.42 Strike price $1.52 $ 0.26 - $ 0.75 $0.43 Forfeiture rate nil nil nil The Company recorded $1,656,184 December 31, 2020 $2,539,092 December 31, 2019. December 31, 2019, $600,000 $154,148 394,735

Note 13 - Warrants

Note 13 - Warrants	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Warrants Note Disclosure [Text Block]	13. Warrants In connection with the February 14, 2020 20,833,334 five one one $0.20. 1,041,667 one $0.15 In connection with the April 9, 2020 16,666,667 five one $0.15. 1,666,667 one $0.15 In connection with the May 29, 2020 133,333,333 two one $0.15. 12,170,000 $0.0001 December 31, 2020, In connection with the July 7, 2020 187,500,000 two one $0.16. 25,000,000 $0.0001 December 31, 2020, As of December 31, 2020, Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.20 20,833,334 4.62 February 14, 2020 0.15 1,041,667 4.12 April 9, 2020 0.15 3,403,752 4.27 May 29, 2020 0.15 37,842,695 1.41 July 7, 2020 0.16 138,899,375 1.52 Balance at December 31, 2020 202,020,823 The fair value of warrants issued during the year ended December 31, 2020 Series A Warrants February 14, 2020 Series A Placement Agent Warrants February 14, 2020 Volatility 87% 87% Risk-free interest rate 1.42% 1.42% Expected life (years) 5.5 5 Dividend yield 0% 0% Common share price $0.12 $0.12 Strike price $0.20 $0.15 Forfeiture rate nil nil Series B Warrants April 9, 2020 Series B Placement Agent Warrants April 9, 2020 Volatility 99% 99% Risk-free interest rate 0.41% 0.41% Expected life (years) 5 5 Dividend yield 0% 0% Common share price $0.14 $0.14 Strike price $0.15 $0.15 Forfeiture rate nil nil Series C Warrants May 29, 2020 Volatility 118% Risk-free interest rate 0.16% Expected life (years) 2 Dividend yield 0% Common share price $0.16 Strike price $0.15 Forfeiture rate nil Series D Warrants July 7, 2020 Volatility 118% Risk-free interest rate 0.16% Expected life (years) 2 Dividend yield 0% Common share price $0.17 Strike price $0.16 Forfeiture rate nil

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income taxes The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 27% 2019 27% For the year ended December 31, 2020 For the year ended December 31, 2019 Loss before income taxes $ (16,911,784 ) $ (19,784,054 ) Expected income tax expense (recovery) (4,058,828 ) (5,341,690 ) Difference in foreign tax rates (74,847 ) 54,660 Tax rate changes and other adjustments 1,540,539 - Stock based compensation and non-deductible expenses 407,689 771,640 Foreign accrual property income 210,605 261,160 Prior period adjustment 32,518 - Share issuance costs recorded in equity (1,282,179 ) (198,930 ) Change in valuation allowance 3,224,503 4,453,160 Total income tax expense $ - $ - The following table summarizes the components of deferred tax: Deferred Tax Assets 2020 2019 Intangible assets - licenses $ 4,236,169 $ 3,622,890 Share issuance costs 1,148,179 301,180 Reserves 28,784 20,410 Non-capital losses carried forward - Canada 6,182,002 5,498,910 Net operating losses carried forward - US 5,091,162 4,154,520 Investment Tax Credits 27,328 27,330 Operating leases 345,937 6,560 Other 466 350 Total deferred tax assets $ 17,060,027 $ 13,632,310 Deferred Tax Liabilities Property and equipment $ (94,218 ) $ (231,240 ) Right-of-use asset $ (340,242 ) Total deferred tax liabilities $ (434,460 ) $ (231,240 ) Valuation allowance $ 16,625,567 $ 13,401,070 Net deferred tax asset $ - $ - No not not 2036 $ 3,763,071 2037 $ 4,278,944 2038 $ 5,416,916 2039 $ 6,773,728 2040 $ 7,523,107 Total $ 27,755,766 The Company's US non-operating income tax losses expire as follows: 2035 $ 856,301 2036 $ 1,484,636 2037 $ 3,831,764 indefinitely (subject to 80% limitation $ 13,422,372 Total $ 19,595,073

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	15. Commitments and contingencies On November 26, 2018, ○ 1 st September 12, 2019, ○ $3,000,000 or ○ $1,500,000 $1.95 ○ 2 nd February 19, 2020 - $2,000,000 ○ 3 rd September 12, 2019, ○ $3,000,000 or ○ $1,500,000 $1.95 ○ 4 th February 19, 2020 - $2,000,000 As of December 31, 2020, On May 10, 2018, • 1 st $3,500,000 • 2 nd $3,500,000 10 As of December 31, 2020, On November 1, 2019, 1:19 01108 November 22, 2019. ® January 21, 2020, February 11, 2020, February 25, 2020. September 30, 2020, October 14, 2020 no not Under the terms of the Development and Supply Agreement, dated November 26, 2018, third

Note 16 - Financial Instruments

Note 16 - Financial Instruments	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	16. Financial instruments (a) Fair values The Company follows ASC topic 820, 820 820 three three three Level 1 Level 2 1 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying values of cash and accounts payable and accrued liabilities approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company's cash is not (c) Foreign exchange risk The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to an FX loss while a weakening U.S. dollar will lead to an FX gain. For each Canadian dollar balance of $1.0 10% $0.1 (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at December 31, 2020 December 31, 2019: December 31, 2020 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,248,628 - - - - 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 1,835,650 62,463 64,356 66,307 1,087,998 3,116,774 December 31, 2019 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,087,525 - - - - 2,087,525 Debt obligations - - - - - - Lease obligations - - - - - - 2,087,525 - - - - 2,087,525

Note 17 - Segmented Information

Note 17 - Segmented Information	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	17. Segmented information The Company's operations comprise a single reportable segment engaged in research and development targeting health and wellness solutions for the companion pet. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in the United States of America (“US”). December 31, December 31, 2020 2019 $ $ Total assets Canada 53,160,701 249,929 US 12,983,333 3,933,055 Total US property and equipment 583,007 729,142 Total US right-of-use asset 1,318,716 1,103,658 1,901,723 1,832,800

Note 18 - Schedule of Expenses

Note 18 - Schedule of Expenses	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Operating Expenses [Text Block]	18. Schedule of expenses For the year ended December 31, 2020 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 557,634 $ - $ 4,336,545 Contracted expenditures 2,064,597 - - Marketing and investor relations - - 261,911 Travel and accommodation 534 - 16,691 Insurance 982 - 231,005 License fees 5,000,000 - - Office 43,918 - 435,415 Consultants 107,029 2,179,082 - Regulatory 151,073 - 430,471 Rent 83,425 - 299,947 Supplies 34,699 - - Total $ 8,043,891 $ 2,179,082 $ 6,011,985 For the year ended December 31, 2019 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 880,818 $ - $ 5,581,358 Contracted expenditures 2,843,998 - - Marketing and investor relations 2,303 - 471,887 Travel and accommodation 37,181 - 435,530 Insurance 5,653 - 125,888 License fees 5,936,841 - - Office 50,599 - 197,815 Consultants 251,096 1,666,089 - Regulatory 127,190 - 106,230 Rent - - 32,473 Supplies 209,612 - 34,153 Total $ 10,345,291 $ 1,666,089 $ 6,985,334

Note 19 - Capital Risk Manageme

Note 19 - Capital Risk Management	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Capital Risk Management [Text Block]	19. Capital risk management The capital of the Company includes equity, which is comprised of issued common shares, common stock subscribed, additional paid-in capital, and accumulated deficit. The Company's objective when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders, and other stakeholders and to maintain a strong capital base to support the Company's core activities.

Note 20 - Loss Per Share

Note 20 - Loss Per Share	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	20. Loss per share For the year ended For the year ended December 31, 2020 December 31, 2019 Numerator Net loss for the year $ 16,911,784 $ 19,784,054 Denominator Weighted average shares - basic 364,444,664 106,297,975 Warrants - - Stock options - - Denominator for diluted loss per share 364,444,664 106,297,975 Loss per share - basic and diluted $ (0.05 ) $ (0.19 ) As of December 31, 2020, 2019, 39,604,515 7,040,265 202,020,823 nil.

Note 21 - Related Party Transac

Note 21 - Related Party Transactions and Key Management Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	21. Related party transactions and key management compensation As of the year ended December 31, 2020, nil December 31, 2019, $169,143. Key management personnel are comprised of the Company's directors and executive officers. In addition to their salaries, key management personnel also receive share-based compensation. Key management personnel compensation is as follows: For the year ended December 31, 2020 For the year ended December 31, 2019 Salaries and benefits, including bonuses $ 1,010,943 $ 1,463,830 Stock-based compensation 1,548,747 1,842,313 Total $ 2,559,690 $ 3,306,143

Note 22 - Comparative Figures

Note 22 - Comparative Figures	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Reclassifications [Text Block]	22. Comparative figures Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no December 31, 2019 not

Note 23 - Subsequent Events

Note 23 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	23. Subsequent events On February 8, 2021, 91,315,790 $1.90 30 13,697,368 February 11, 2021, $173.5 February 16, 13,697,368 $1.90 $26.0

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of the consolidated financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.
Basis of Measurement [Policy Text Block]	Basis of measurement The consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.
Functional and Reporting Currencies [Policy Text Block]	Functional and reporting currencies The Company's and subsidiary's functional currency, as determined by management, is US dollars, which is also the Company's reporting currency.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid securities with an original maturity of three The financial risks associated with these instruments are minimal and the Company has not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are carried at historical cost less accumulated depreciation and any accumulated impairment losses. Maintenance and repair expenditures that do not Depreciation is recognized so as to write off the cost less their residual values over their useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. An item of property and equipment is derecognized upon disposal or when no Estimated useful lives for the principal asset categories are as follows: Computer equipment (years) 3 Furniture and equipment (years) 5 - 7 Laboratory equipment (years) 5 - 7 Leasehold improvements Over shorter of estimated useful life and lease term
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of long-lived assets Long-lived assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not less than its carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value.
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730.
Share Issue Costs [Policy Text Block]	Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign currencies In respect of transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries' functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are measured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these transactions are recognized in the consolidated statements of operations and comprehensive loss.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during fiscal 2020 2019 not December 31, 2020 2019
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss The Company follows ASC topic 220. no
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible assets Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful lives and amortization methods are reviewed at the end of each year, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses. Computer software and website (years) 3 Trademarks (years) 15
Fair Value Measurement, Policy [Policy Text Block]	Fair value measurement Under ASC topic 820, 820 three l Level 1 l Level 2 1 2 not l Level 3 The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
Income Tax, Policy [Policy Text Block]	Income taxes The Company accounts for income taxes in accordance with Accounting Standard Codification 740, 740" Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not not The Company assesses the likelihood of the financial statement effect of an uncertain tax position that should be recognized when it is more likely than not not ASC 740 740 December 31, 2020 2019, not 740.
Segment Reporting, Policy [Policy Text Block]	Segmented reporting The Company currently operates as a single segment. Its principal business relates to the discovery, development and commercialization of innovative pharmaceuticals for the companion pet.

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]	Computer equipment (years) 3 Furniture and equipment (years) 5 - 7 Laboratory equipment (years) 5 - 7 Leasehold improvements Over shorter of estimated useful life and lease term
Estimated Lives of Finite-Lived Intangible Assets [Table Text Block]	Computer software and website (years) 3 Trademarks (years) 15

Note 5 - Prepaid Expenses, De_2

Note 5 - Prepaid Expenses, Deposits and Deferred Financing Costs (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Prepaid Expenses and Deposits [Table Text Block]	December 31, December 31, 2020 2019 Deposits (i) 1,455,119 1,033,231 Prepaid marketing (ii) 26,330 19,829 Prepaid insurance (ii) 184,154 110,636 Other (iii) 62,211 64,889 Total $ 1,727,814 $ 1,228,585

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2018 $ 170,002 $ 181,879 $ 352,637 $ 282,975 $ 987,493 Additions 218,076 3,415 3,350 65,672 290,513 Disposals (2,210 ) - - - (2,210 ) Balance at December 31, 2019 385,868 185,294 355,987 348,647 1,275,796 Additions 1,944 - - 299,268 301,212 Disposals (23,648 ) (64,013 ) (121,900 ) (76,455 ) (286,016 ) Balance at December 31, 2020 364,165 121,281 234,087 571,460 1,290,993 Accumulated depreciation Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 88,417 26,617 68,519 93,597 277,150 Disposals (901 ) - - - (901 ) Balance at December 31, 2019 192,434 56,202 168,215 129,803 546,654 Depreciation 86,382 18,588 65,668 135,276 305,914 Disposals (22,370 ) (29,279 ) (55,702 ) (37,231 ) (144,582 ) Balance at December 31, 2020 256,446 45,511 178,181 227,848 707,986 Net book value as at: December 31, 2019 $ 193,434 $ 129,092 $ 187,772 $ 218,844 $ 729,142 December 31, 2020 $ 107,719 $ 75,770 $ 55,906 $ 343,612 $ 583,007

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Computer software Trademarks Website Warranty Total intangible assets Cost Balance at December 31, 2018 22,882 16,236 - - 21,379 Additions - - 513,680 - 531,419 Balance at December 31, 2019 22,882 16,236 513,680 - 552,798 Additions - - - 14,850 14,850 Balance at December 31, 2020 22,882 16,236 513,680 14,850 567,648 Accumulated amortization Balance at December 31, 2018 5,143 3,178 - - 8,321 Amortization - 1,082 - - 1,082 Balance at December 31, 2019 5,143 4,260 - - 9,403 Amortization 5,996 1,095 173,641 926 181,658 Balance at December 31, 2020 11,139 5,355 173,641 926 191,061 Net book value as at: December 31, 2019 $ 17,739 $ 11,976 $ 513,680 - $ 543,395 December 31, 2020 $ 11,743 $ 10,881 $ 340,039 $ 13,924 $ 376,587
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2021 $ 184,139 2022 176,832 2023 1,076 2024 1,076 2025 1,076 Total $ 364,199

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lessee, Operating Lease, Right of Use Asset and Lease Liabilities [Table Text Block]	Right-of-use asset Premise lease Cost Aggregate lease commitments $ 2,067,505 Less: impact of present value (513,894 ) Balance at December 31, 2020 1,553,611 Reduction in right-of-use asset Straight line amortization 379,043 Interest (144,148 ) Balance at December 31, 2020 234,895 Net book value as of: December 31, 2020 $ 1,318,716 Lease liabilities Premise lease Additions $ 1,553,611 Payments (356,972 ) Interest 144,147 Total lease liabilities at December 31, 2020 1,340,786 Current portion of lease liabilities 252,788 Long term portion of lease liabilities 1,087,998 Total lease liabilities at December 31, 2020 $ 1,340,786
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 400,133 2022 412,137 2023 424,501 2024 437,236 2025 36,526 Total $ 1,710,533

Note 10 - Preferred Stock (Tabl

Note 10 - Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Preferred Stock [Table Text Block]	Number of Preferred preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing 12 $ 11,961,397 Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 $ 11,961,397

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Number of common Common stock stock amount Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issuance for services (i and ii) 707,236 792,104 Stock issued from financing (iii and iv) 9,337,529 6,609,920 Stock issued due to exercise of options 394,735 754,148 Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (v,vi,vii,viii) 337,830,001 29,295,671 Stock issued from the financing and exercise of prefunded warrants (vii and viii) 37,146,984 12,581,987 Stock issued from the exercise of warrants (ix, x, xi) 159,020,845 24,339,134 Balance at December 31, 2020 642,036,228 $ 104,783,612

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of options Weighted avg exercise price Balance at December 31, 2018 422,044 1.95 Stock options granted January 10, 2019 5,995,000 1.52 Stock options expired February 24, 2019 (35,000 ) 1.15 Stock options exercised March 8, 2019 (164,473 ) 1.52 Stock options exercised March 15, 2019 (164,473 ) 1.52 Stock options exercised March 29, 2019 (65,789 ) 1.52 Stock options expired May 23, 2019 (10,000 ) 1.52 Stock options expired June 16, 2019 (40,000 ) 1.52 Stock options cancelled July 14, 2019 (5,000 ) 1.52 Stock options cancelled August 13, 2019 (5,000 ) 1.52 Stock options expired August 14, 2019 (387,004 ) 2.11 Stock options granted August 19, 2019 500,000 0.26 Stock options granted August 19, 2019 100,000 0.35 Stock options granted August 19, 2019 100,000 0.45 Stock options granted August 19, 2019 100,000 0.55 Stock options granted August 19, 2019 100,000 0.65 Stock options granted August 19, 2019 100,000 0.75 Stock options granted September 16, 2019 500,000 0.43 Balance at December 31, 2019 7,040,265 $ 1.28 Stock options forfeited January 23, 2020 (50,000 ) 1.52 Stock options forfeited February 25, 2020 (5,000 ) 1.12 Stock options forfeited March 1, 2020 (50,000 ) 1.52 Stock options granted March 14, 2020 5,056,000 0.19 Stock options forfeited April 21, 2020 (150,000 ) 0.19 Stock options forfeited May 4, 2019 (15,000 ) 0.19 Stock options forfeited May 5, 2020 (30,000 ) 1.52 Stock options forfeited May 7, 2020 (15,000 ) 1.52 Stock options forfeited June 11, 2020 (15,000 ) 1.52 Stock options granted June 16, 2020 2,000,000 0.19 Stock options granted July 9, 2020 175,000 0.18 Stock options forfeited July 20, 2020 (400,000 ) 1.52 Stock options forfeited July 20, 2020 (50,000 ) 0.19 Stock options forfeited July 31, 2020 (3,750 ) 0.19 Stock options forfeited August 2, 2020 (10,000 ) 1.52 Stock options forfeited August 2, 2020 (5,000 ) 0.19 Stock options forfeited August 14, 2020 (675,000 ) 0.19 Stock options forfeited August 19, 2020 (75,375 ) 0.19 Stock options granted August 25, 2020 40,000 0.13 Stock options forfeited September 25, 2020 (37,500 ) 0.19 Stock options granted September 29, 2020 300,000 0.11 Stock options granted October 1, 2020 300,000 0.11 Stock options forfeited October 15, 2020 (56,250 ) 0.19 Stock options granted October 20, 2020 40,000 0.09 Stock options forfeited October 29, 2020 (1,250 ) 0.19 Stock options forfeited November 12, 2020 (225,000 ) 0.19 Stock options forfeited November 12, 2020 (950,000 ) 1.52 Stock options forfeited November 17, 2020 (25,125 ) 0.19 Stock options forfeited November 17, 2020 (50,000 ) 1.52 Stock options forfeited December 24, 2020 (12,500 ) 0.19 Stock options granted December 31, 2020 27,560,000 0.23 Balance at December 31, 2020 39,604,515 $ 0.36 Vested at December 31, 2020 14,624,140 $ 0.59
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) January 10, 2019 $ 1.52 5,540,265 5,540,265 - 1.03 August 19, 2019 0.26 500,000 500,000 - 1.64 August 19, 2019 0.35 100,000 100,000 - 1.64 August 19, 2019 0.45 100,000 100,000 - 1.64 August 19, 2019 0.55 100,000 100,000 - 1.64 August 19, 2019 0.65 100,000 100,000 - 1.64 August 19, 2019 0.75 100,000 100,000 - 1.64 September 16, 2019 0.43 500,000 500,000 - 1.71 Balance at December 31, 2019 7,040,265 7,040,265 - Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) January 10, 2019 1.52 3,965,265 3,965,265 - 0.03 August 19, 2019 0.26 500,000 500,000 - 0.63 August 19, 2019 0.35 100,000 100,000 - 0.63 August 19, 2019 0.45 100,000 100,000 - 0.63 August 19, 2019 0.55 100,000 100,000 - 0.63 August 19, 2019 0.65 100,000 100,000 - 0.63 August 19, 2019 0.75 100,000 100,000 - 0.63 September 16, 2019 0.43 500,000 500,000 - 0.71 March 14, 2020 0.19 3,724,250 945,125 2,779,125 4.20 June 16, 2020 0.19 2,000,000 2,000,000 - 4.46 July 9, 2020 0.18 175,000 43,750 131,250 4.52 August 25, 2020 0.13 40,000 10,000 30,000 4.65 September 29, 2020 0.11 300,000 75,000 225,000 4.75 October 1, 2020 0.11 300,000 75,000 225,000 4.75 October 20, 2020 0.09 40,000 10,000 30,000 4.81 December 31, 2020 0.23 27,560,000 6,000,000 21,560,000 10.00 Balance at December 31, 2020 39,604,515 14,624,140 24,980,375
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	July 9, 2020 June 16, 2020 March 14, 2020 Volatility 100% 100% 87% Risk-free interest rate 0.28% 0.21% 0.49% Expected life (years) 5 5 5 Divedend yield 0% 0% 0% Common share price $0.17 $0.19 $0.18 Strike price $0.18 $0.19 $0.19 Forfeiture rate nil nil nil October 1, 2020 September 29, 2020 August 25, 2020 Volatility 100% 100% 99% Risk-free interest rate 0.27% 0.24% 0.30% Expected life (years) 5 5 5 Dividend yield 0% 0% 0% Common share price $0.10 $0.10 $0.13 Strike price $0.11 $0.11 $0.13 Forfeiture rate nil nil nil December 31, 2020 October 20, 2020 Volatility 102% 100% Risk-free interest rate 0.51% 0.34% Expected life (years) 5.75 5 Dividend yield 0% 0% Common share price $0.23 $0.08 Strike price $0.23 $0.09 Forfeiture rate nil nil January 10, 2019 August 19, 2019 September 16, 2019 Volatility 68% 87% 89% Risk-free interest rate 2.56% 1.48% 1.74% Expected life (years) 2 2 2 Dividend yield 0 0 0 Common share price $1.23 $0.26 $0.42 Strike price $1.52 $ 0.26 - $ 0.75 $0.43 Forfeiture rate nil nil nil

Note 13 - Warrants (Tables)

Note 13 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.20 20,833,334 4.62 February 14, 2020 0.15 1,041,667 4.12 April 9, 2020 0.15 3,403,752 4.27 May 29, 2020 0.15 37,842,695 1.41 July 7, 2020 0.16 138,899,375 1.52 Balance at December 31, 2020 202,020,823
Schedule of Warrant or Right Outstanding and Options, Valuation Assumptions [Table Text Block]	Series A Warrants February 14, 2020 Series A Placement Agent Warrants February 14, 2020 Volatility 87% 87% Risk-free interest rate 1.42% 1.42% Expected life (years) 5.5 5 Dividend yield 0% 0% Common share price $0.12 $0.12 Strike price $0.20 $0.15 Forfeiture rate nil nil Series B Warrants April 9, 2020 Series B Placement Agent Warrants April 9, 2020 Volatility 99% 99% Risk-free interest rate 0.41% 0.41% Expected life (years) 5 5 Dividend yield 0% 0% Common share price $0.14 $0.14 Strike price $0.15 $0.15 Forfeiture rate nil nil Series C Warrants May 29, 2020 Volatility 118% Risk-free interest rate 0.16% Expected life (years) 2 Dividend yield 0% Common share price $0.16 Strike price $0.15 Forfeiture rate nil Series D Warrants July 7, 2020 Volatility 118% Risk-free interest rate 0.16% Expected life (years) 2 Dividend yield 0% Common share price $0.17 Strike price $0.16 Forfeiture rate nil

Note 14 - Income Taxes (Tables)

Note 14 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the year ended December 31, 2020 For the year ended December 31, 2019 Loss before income taxes $ (16,911,784 ) $ (19,784,054 ) Expected income tax expense (recovery) (4,058,828 ) (5,341,690 ) Difference in foreign tax rates (74,847 ) 54,660 Tax rate changes and other adjustments 1,540,539 - Stock based compensation and non-deductible expenses 407,689 771,640 Foreign accrual property income 210,605 261,160 Prior period adjustment 32,518 - Share issuance costs recorded in equity (1,282,179 ) (198,930 ) Change in valuation allowance 3,224,503 4,453,160 Total income tax expense $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred Tax Assets 2020 2019 Intangible assets - licenses $ 4,236,169 $ 3,622,890 Share issuance costs 1,148,179 301,180 Reserves 28,784 20,410 Non-capital losses carried forward - Canada 6,182,002 5,498,910 Net operating losses carried forward - US 5,091,162 4,154,520 Investment Tax Credits 27,328 27,330 Operating leases 345,937 6,560 Other 466 350 Total deferred tax assets $ 17,060,027 $ 13,632,310 Deferred Tax Liabilities Property and equipment $ (94,218 ) $ (231,240 ) Right-of-use asset $ (340,242 ) Total deferred tax liabilities $ (434,460 ) $ (231,240 ) Valuation allowance $ 16,625,567 $ 13,401,070 Net deferred tax asset $ - $ -
Non-capital and Non-operating Loss Carryforward [Table Text Block]	2036 $ 3,763,071 2037 $ 4,278,944 2038 $ 5,416,916 2039 $ 6,773,728 2040 $ 7,523,107 Total $ 27,755,766 2035 $ 856,301 2036 $ 1,484,636 2037 $ 3,831,764 indefinitely (subject to 80% limitation $ 13,422,372 Total $ 19,595,073

Note 16 - Financial Instrumen_2

Note 16 - Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]	December 31, 2020 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,248,628 - - - - 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 1,835,650 62,463 64,356 66,307 1,087,998 3,116,774 December 31, 2019 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,087,525 - - - - 2,087,525 Debt obligations - - - - - - Lease obligations - - - - - - 2,087,525 - - - - 2,087,525

Note 17 - Segmented Informati_2

Note 17 - Segmented Information (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	December 31, December 31, 2020 2019 $ $ Total assets Canada 53,160,701 249,929 US 12,983,333 3,933,055 Total US property and equipment 583,007 729,142 Total US right-of-use asset 1,318,716 1,103,658 1,901,723 1,832,800

Note 18 - Schedule of Expenses

Note 18 - Schedule of Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Operating Expenses [Table Text Block]	For the year ended December 31, 2020 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 557,634 $ - $ 4,336,545 Contracted expenditures 2,064,597 - - Marketing and investor relations - - 261,911 Travel and accommodation 534 - 16,691 Insurance 982 - 231,005 License fees 5,000,000 - - Office 43,918 - 435,415 Consultants 107,029 2,179,082 - Regulatory 151,073 - 430,471 Rent 83,425 - 299,947 Supplies 34,699 - - Total $ 8,043,891 $ 2,179,082 $ 6,011,985 For the year ended December 31, 2019 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 880,818 $ - $ 5,581,358 Contracted expenditures 2,843,998 - - Marketing and investor relations 2,303 - 471,887 Travel and accommodation 37,181 - 435,530 Insurance 5,653 - 125,888 License fees 5,936,841 - - Office 50,599 - 197,815 Consultants 251,096 1,666,089 - Regulatory 127,190 - 106,230 Rent - - 32,473 Supplies 209,612 - 34,153 Total $ 10,345,291 $ 1,666,089 $ 6,985,334

Note 20 - Loss Per Share (Table

Note 20 - Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the year ended For the year ended December 31, 2020 December 31, 2019 Numerator Net loss for the year $ 16,911,784 $ 19,784,054 Denominator Weighted average shares - basic 364,444,664 106,297,975 Warrants - - Stock options - - Denominator for diluted loss per share 364,444,664 106,297,975 Loss per share - basic and diluted $ (0.05 ) $ (0.19 )

Note 21 - Related Party Trans_2

Note 21 - Related Party Transactions and Key Management Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Key Management Personnel Compensation [Table Text Block]	For the year ended December 31, 2020 For the year ended December 31, 2019 Salaries and benefits, including bonuses $ 1,010,943 $ 1,463,830 Stock-based compensation 1,548,747 1,842,313 Total $ 2,559,690 $ 3,306,143

Note 3 - Significant Accounti_3

Note 3 - Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Other Comprehensive Income (Loss), Net of Tax, Total	$ 0	$ 0

Note 3 - Significant Accounti_4

Note 3 - Significant Accounting Policies - Estimated Useful Lives for the Principal Asset Categories (Details)	12 Months Ended
	Dec. 31, 2020
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	Over shorter of estimated useful life and lease term

Note 3 - Significant Accounti_5

Note 3 - Significant Accounting Policies - Estimated Useful Lives of Finite-lived Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2020
Computer Software and Website, Intangible Asset [Member]
Computer software and website (years) (Year)	3 years
Trademarks [Member]
Computer software and website (years) (Year)	15 years

Note 5 - Prepaid Expenses, De_3

Note 5 - Prepaid Expenses, Deposits and Deferred Financing Costs (Details Textual) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Deposits, Noncurrent	$ 1,000,000	$ 0

Note 5 - Prepaid Expenses, De_4

Note 5 - Prepaid Expenses, Deposits and Deferred Financing Costs - Summary of Prepaid Expenses, Deposits and Deferred Financing Costs (Details) - USD ($)		Dec. 31, 2020	Dec. 31, 2019
Deposits	[1]	$ 1,455,119	$ 1,033,231
Prepaid marketing	[2]	26,330	19,829
Prepaid insurance	[2]	184,154	110,636
Other	[3]	62,211	64,889
Total		$ 1,727,814	$ 1,228,585
[1]	Deposits include payments made to vendors in advance and are primarily associated with, research activity, leasing deposits and costs for additional office space. As of December 31, 2020, and December 31, 2019, the Company classified $1,000,000 and nil as a non-current asset, with the remainder classified as a current asset in the consolidated balance sheet;
[2]	As of December 31, 2020, and December 31, 2019, all amounts were classified as a current asset in the consolidated balance sheet;
[3]	Other is comprised of deferred financing costs, subscription payments, utilities, travel costs and software licensing. As of December 31, 2020, and December 31, 2019, the Company classified all amounts as a current asset in the consolidated balance sheet.

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Feb. 29, 2020
Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset	$ 141,434	$ 1,308
Proceeds from Sales of Assets, Investing Activities	20,400	0
Gain (Loss) on Disposition of Property Plant Equipment, Total	(121,034)	(1,308)
Property, Plant and Equipment, Net, Ending Balance	583,007	729,142
Reclassification of Prepaid Expenses to Leasehold Improvements [Member]
Prepaid Expense			$ (299,268)
Leasehold Improvements [Member]
Property, Plant and Equipment, Net, Ending Balance	$ 343,612	$ 218,844
Leasehold Improvements [Member] | Reclassification of Prepaid Expenses to Leasehold Improvements [Member]
Property, Plant and Equipment, Net, Ending Balance			$ 299,268

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cost, Beginning Balance	$ 1,275,796	$ 987,493
Cost, Additions	301,212	290,513
Cost, Disposals	(286,016)	(2,210)
Cost, Ending Balance	1,290,993	1,275,796
Accumulated Depreciation, Beginning Balance	546,654	270,405
Accumulated Depreciation, Depreciation	305,914	277,150
Accumulated Depreciation, Disposals	(144,582)	(901)
Accumulated Depreciation, Ending Balance	707,986	546,654
Property, Plant and Equipment, Net, Ending Balance	583,007	729,142
Computer Equipment [Member]
Cost, Beginning Balance	385,868	170,002
Cost, Additions	1,944	218,076
Cost, Disposals	(23,648)	(2,210)
Cost, Ending Balance	364,165	385,868
Accumulated Depreciation, Beginning Balance	192,434	104,918
Accumulated Depreciation, Depreciation	86,382	88,417
Accumulated Depreciation, Disposals	(22,370)	(901)
Accumulated Depreciation, Ending Balance	256,446	192,434
Property, Plant and Equipment, Net, Ending Balance	107,719	193,434
Furniture and Fixtures [Member]
Cost, Beginning Balance	185,294	181,879
Cost, Additions		3,415
Cost, Disposals	(64,013)
Cost, Ending Balance	121,281	185,294
Accumulated Depreciation, Beginning Balance	56,202	29,585
Accumulated Depreciation, Depreciation	18,588	26,617
Accumulated Depreciation, Disposals	(29,279)
Accumulated Depreciation, Ending Balance	45,511	56,202
Property, Plant and Equipment, Net, Ending Balance	75,770	129,092
Laboratory Equipment [Member]
Cost, Beginning Balance	355,987	352,637
Cost, Additions		3,350
Cost, Disposals	(121,900)
Cost, Ending Balance	234,087	355,987
Accumulated Depreciation, Beginning Balance	168,215	99,696
Accumulated Depreciation, Depreciation	65,668	68,519
Accumulated Depreciation, Disposals	(55,702)
Accumulated Depreciation, Ending Balance	178,181	168,215
Property, Plant and Equipment, Net, Ending Balance	55,906	187,772
Leasehold Improvements [Member]
Cost, Beginning Balance	348,647	282,975
Cost, Additions	299,268	65,672
Cost, Disposals	(76,455)
Cost, Ending Balance	571,460	348,647
Accumulated Depreciation, Beginning Balance	129,803	36,206
Accumulated Depreciation, Depreciation	135,276	93,597
Accumulated Depreciation, Disposals	(37,231)
Accumulated Depreciation, Ending Balance	227,848	129,803
Property, Plant and Equipment, Net, Ending Balance	$ 343,612	$ 218,844

Note 7 - Intangible Assets - Fi

Note 7 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cost, Beginning Balance	$ 552,798	$ 21,379
Cost, Additions	14,850	531,419
Cost, Ending Balance	567,648	552,798
Accumulated Amortization, Beginning Balance	9,403	8,321
Accumulated Amortization, Amortization	181,658	1,082
Accumulated Amortization, Ending Balance	191,061	9,403
Net Book Value	376,587	543,395
Computer Software, Intangible Asset [Member]
Cost, Beginning Balance	22,882	22,882
Cost, Additions
Cost, Ending Balance	22,882	22,882
Accumulated Amortization, Beginning Balance	5,143	5,143
Accumulated Amortization, Amortization	5,996
Accumulated Amortization, Ending Balance	11,139	5,143
Net Book Value	11,743	17,739
Trademarks [Member]
Cost, Beginning Balance	16,236	16,236
Cost, Additions
Cost, Ending Balance	16,236	16,236
Accumulated Amortization, Beginning Balance	4,260	3,178
Accumulated Amortization, Amortization	1,095	1,082
Accumulated Amortization, Ending Balance	5,355	4,260
Net Book Value	10,881	11,976
Website [Member]
Cost, Beginning Balance	513,680
Cost, Additions		513,680
Cost, Ending Balance	513,680	513,680
Accumulated Amortization, Beginning Balance
Accumulated Amortization, Amortization	173,641
Accumulated Amortization, Ending Balance	173,641
Net Book Value	340,039	513,680
Warranty [Member]
Cost, Beginning Balance
Cost, Additions	14,850
Cost, Ending Balance	14,850
Accumulated Amortization, Beginning Balance
Accumulated Amortization, Amortization	926
Accumulated Amortization, Ending Balance	926
Net Book Value	$ 13,924

Note 7 - Intangible Assets - Es

Note 7 - Intangible Assets - Estimated Future Amortization of Intangible (Details)	Dec. 31, 2020USD ($)
2021	$ 184,139
2022	176,832
2023	1,076
2024	1,076
2025	1,076
Total	$ 364,199

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	Feb. 01, 2020USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Number of Lease Agreements				2
Operating Lease, Right-of-Use Asset, Amortization Expense			$ 42,448	$ 509,381
Increase (Decrease) in Prepaid Rent			1,002,113
Operating Lease, Impairment Loss			59,097
Operating Lease, Right-of-Use Asset			1,318,716	1,103,658
General and Administrative Expense [Member]
Operating Lease, Expense			4,331	32,473
Lease Agreement with Wickfield Phoenix LLC [Member]
Lessee, Operating Lease, Term of Contract (Month)	5 years
Operating Lease, Right-of-Use Asset	$ 1,553,611
Lessee, Operating Lease, Discount Rate	12.00%
Operating Lease, Expense			379,041	0
Lease Agreement with Wickfield Phoenix LLC [Member] | Research and Development Expense [Member]
Operating Lease, Expense			83,425	0
Lease Agreement with Wickfield Phoenix LLC [Member] | General and Administrative Expense [Member]
Operating Lease, Expense			$ 295,616	$ 0
Lease Agreement with Wickfield Phoenix LLC [Member] | Minimum [Member]
Monthly Rent Payment	$ 32,452
Lease Agreement with Wickfield Phoenix LLC [Member] | Maximum [Member]
Monthly Rent Payment	36,525
Lease Cancellation [Member]
Increase (Decrease) in Prepaid Rent	1,002,113
Operating Lease, Right-of-Use Asset, Lease Cancellation	1,061,210
Operating Lease, Impairment Loss	$ 59,097
Accounting Standards Update 2016-02 [Member]
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability		$ 1,613,039

Note 8 - Leases - Right of Use

Note 8 - Leases - Right of Use Asset and Lease Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Aggregate lease commitments	$ 2,067,505
Less: impact of present value	(513,894)
Cost, balance	1,553,611
Straight line amortization	379,043
Interest	(144,148)
Reduction in right-of-use asset, balance	234,895
Net book value	1,318,716	$ 1,103,658
Additions	1,553,611
Payments	(356,972)
Interest	144,147
Total lease liabilities at December 31, 2020	1,340,786
Current portion of lease liabilities	252,788
Long term portion of lease liabilities	$ 1,087,998

Note 8 - Leases - Remaining Und

Note 8 - Leases - Remaining Undiscounted Lease Liabilities (Details)	Dec. 31, 2020USD ($)
2021	$ 400,133
2022	412,137
2023	424,501
2024	437,236
2025	36,526
Total	$ 1,710,533

Note 9 - Loan Arrangements (Det

Note 9 - Loan Arrangements (Details Textual) - USD ($)	Oct. 18, 2017	Dec. 31, 2020	Dec. 31, 2019
Long-term Debt, Total		$ 527,360
Proceeds from Short-term Debt, Total		527,360
Loan Arrangement With Shareholder [Member]
Debt Agreement, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term (Year)	5 years
Debt Agreement, Minimum Borrowing Per Advances	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Long-term Debt, Total		0
Paycheck Protection Program CARES Act [Member]
Proceeds from Short-term Debt, Total		$ 527,360

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred Stock, Shares Authorized (in shares)	20	20
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized (in shares)	20
Preferred Stock, Stated Value Per Share (in dollars per share)	$ 1,000,000
Net Sales Payments, Percentage of Sales	9.00%

Note 10 - Preferred Stock - Iss

Note 10 - Preferred Stock - Issued and Outstanding Preferred Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2018
Balance, number (in shares)	12	12
Balance, amount	$ 11,961,397
Series 1 Preferred Shares [Member]
Balance, number (in shares)	12	12
Balance, amount	$ 11,961,397	$ 11,961,397
Stock issued from financing, number (in shares)	12
Stock issued from financing, amount	$ 11,961,397

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual) - USD ($)	Jul. 07, 2020	May 29, 2020	Apr. 09, 2020	Feb. 14, 2020	Mar. 28, 2019	Jan. 14, 2019	Jul. 31, 2020	Jun. 30, 2020	Feb. 29, 2020	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Gain (Loss) on Settlement of Liabilities												$ 19,737
Research and Development Expense, Total											8,043,891	10,345,291
Payments of Stock Issuance Costs											5,107,616	708,683
Proceeds from Issuance of Common Stock											$ 56,496,283	3,000,000
Class of Warrant or Right, Issued During Period (in shares)											202,020,823
Issuance of Common Shares and Warrants, Direct Costs of Issuance	$ 2,268,215	$ 1,908,202	$ 582,977						$ 348,220		$ 5,107,616
Adjustments to Equity, Warrant Issued
Stock Issued During Period, Shares, Exercise of Warrants and Pre-funded Warrants (in shares)							24,984,492	12,162,492
Proceeds from Warrant Exercises											24,339,134	600,000
Common Stock [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance	1,224,218	1,088,876	428,283						238,217		2,979,594
Adjustments to Equity, Warrant Issued											$ (154,767)
Stock Issued During Period, Shares, Exercise of Warrants and Pre-funded Warrants (in shares)											196,167,829
Additional Paid-in Capital [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance	$ 1,043,997	$ 819,327	$ 154,694						110,003		$ 2,128,022
Adjustments to Equity, Warrant Issued											$ 154,767
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Class of Warrant or Right, Period Exerciseable (Month)				180 days
Warrants and Rights Outstanding, Term (Year)				5 years 182 days
Class of Warrant or Right, Issued During Period (in shares)				20,833,334
Class of Warrant or Right, Issued During Period, Value				$ 794,345
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,666,667	1,041,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15	$ 0.15
Warrants and Rights Outstanding, Term (Year)			5 years	5 years
Class of Warrant or Right, Issued During Period (in shares)			1,666,667	1,041,667
Adjustments to Equity, Warrant Issued			$ 161,714						52,496
Placement Agent Warrants [Member] | Common Stock [Member]
Adjustments to Equity, Warrant Issued			118,951						35,816
Placement Agent Warrants [Member] | Additional Paid-in Capital [Member]
Adjustments to Equity, Warrant Issued			$ 42,763						$ 16,680
Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Issued During Period (in shares)			16,666,667
Proceeds from Issuance of Warrants			$ 1,057,752
Class of Warrant or Right, Exercised During Period (in shares)											14,929,582
Proceeds from Warrant Exercises											$ 2,237,437
Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		133,333,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15
Warrants and Rights Outstanding, Term (Year)		2 years
Class of Warrant or Right, Issued During Period (in shares)		133,333,333
Proceeds from Issuance of Warrants		$ 7,582,072
Class of Warrant or Right, Exercised During Period (in shares)											95,490,638
Proceeds from Warrant Exercises											$ 14,323,596
Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001	$ 0.0001
Class of Warrant or Right, Issued During Period (in shares)	25,000,000	12,170,000
Proceeds from Issuance of Warrants	$ 2,329,983	$ 1,080,289
Public Offering with One Pre-funded Warrant and One Series C Warrant [Member]
Offering Price (in dollars per share)		$ 0.1499
Series D Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	187,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.16
Warrants and Rights Outstanding, Term (Year)	2 years
Proceeds from Issuance of Warrants	$ 11,376,575
Class of Warrant or Right, Exercised During Period (in shares)											48,600,625
Proceeds from Warrant Exercises											$ 7,776,101
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						2,815,789
Proceeds from Issuance of Private Placement										$ 4,280,000
Payments of Stock Issuance Costs						$ 465
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	162,500,000	121,163,333			6,521,740
Payments of Stock Issuance Costs												$ 669,615
Proceeds from Issuance of Common Stock			2,942,248		$ 3,000,000
Shares Issued, Number of Common Shares Per Share (in shares)	1	1
Proceeds from Issuance or Sale of Equity, Total	$ 29,997,500	$ 19,998,783	$ 4,000,000
Stock Issued During Period, Value, New Issues	$ 16,290,941	$ 11,336,422
Stock and Warrants Issued During Period, Shares, New Issues (in shares)			33,333,334
Offering Price (in dollars per share)			$ 0.12
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				20,833,334
Shares Issued, Number of Common Shares Per Share (in shares)				1
Shares Issued, Price Per Share (in dollars per share)				$ 0.12
Proceeds from Issuance or Sale of Equity, Total				$ 2,500,000
Stock Issued During Period, Value, New Issues				$ 1,705,655
Public Offering with One Common Share and One Series C Warrant [Member]
Offering Price (in dollars per share)		$ 0.15
Public Offering With One Common Share and One Series D Warrant [Member]
Offering Price (in dollars per share)	$ 0.16
Public Offering With One Pre-funded Warrant and One Series D Warrant [Member]
Offering Price (in dollars per share)	$ 0.1599
One Creditor [Member]
Debt Conversion, Converted Instrument, Amount						$ 75,000
Common Stock, Number of Shares, Issued (in shares)						49,342
Common Stock, Value, Issued						$ 55,263
Gain (Loss) on Settlement of Liabilities						$ 19,737
Celsee [Member]
Common Stock, Number of Shares, Issued (in shares)						657,894
Common Stock, Value, Issued						$ 1,000,000
Research and Development Expense, Total						$ 736,841

Note 11 - Common Stock - Issued

Note 11 - Common Stock - Issued and Outstanding Common Shares (Details) - USD ($)		Mar. 29, 2019	Mar. 15, 2019	Mar. 08, 2019	Dec. 31, 2020		Dec. 31, 2019
Number of common shares (in shares)					108,038,398
Stock issuance for services					$ 56,496,283		$ 792,104
Stock issued from financing							$ 14,291,317
Stock issuance due to exercise of options (in shares)		65,789	164,473	164,473	0		394,735
Stock issuance due to exercise of options							$ 600,000
Number of common shares (in shares)					642,036,228		108,038,398
Common Stock [Member]
Number of common shares (in shares)					108,038,398		97,598,898
Capital stock					$ 38,566,820		$ 30,410,648
Stock issuance for services (in shares)					337,830,001		707,236	[1],[2]
Stock issuance for services					$ 32,275,265		$ 792,104	[1],[2]
Stock issuance for financing, net of cost (in shares)					337,830,001	[3],[4],[5],[6]	9,337,529	[7],[8]
Stock issued from financing					$ 29,295,671	[3],[4],[5],[6]	$ 6,609,920	[7],[8]
Stock issuance due to exercise of options (in shares)							394,735
Stock issuance due to exercise of options							$ 754,148
Stock issued from the financing and exercise of prefunded warrants (in shares)	[5],[6]				37,146,984
Stock issued from the financing and exercise of prefunded warrants (vii and viii)	[5],[6]				$ 12,581,987
Stock issued from the exercise of warrants (in shares)	[9],[10],[11]				159,020,845
Stock issued from the exercise of warrants	[9],[10],[11]				$ 24,339,134
Number of common shares (in shares)					642,036,228		108,038,398
Capital stock					$ 104,783,612		$ 38,566,820
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance.
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities in the consolidated statement of loss and comprehensive loss;
[3]	On April 9, 2020 the Company completed a confidentially marketed public offering ("CMPO") of its common shares and warrants ("Series B Warrants") of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares. The securities were sold in a fixed combination of one common share and 0.5 of a Series B Warrant at a combined offering price of $0.12 per share and accompanying warrant. Each whole warrant is exercisable immediately for one common share after issuance, at an exercise price of $0.15 per share and has a term of 5 years. The Company also issued warrants to the placement agents to purchase 1,666,667 common shares at an exercise price of $0.15 per share ("Series B Placement Agent Warrants"), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 33,333,334 common shares, 16,666,667 Series B Warrants, and an additional 1,666,667 Series B Placement Agent Warrants. The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders' equity using the relative fair value approach. The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares and warrants issued in April were $582,977. These direct costs were recorded as an offset against the statement of shareholders' equity with $428,283 being recorded under capital stock and $154,694 being recorded under additional paid-in-capital. The Company also recorded the value of the Series B Placement Agent Warrants in the amount of $161,714 as an offset against the statement of shareholders' equity, with $118,951 being recorded under capital stock and $42,763 being recorded under additional paid-in-capital.
[4]	On February 14, 2020, the Company completed a registered direct offering ("RDO") of its common shares and a simultaneous private placement of its warrants ("Series A Warrants") in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5- and one-half years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share ("Series A Placement Agent Warrants"), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants, and an additional 1,041,667 Series A Placement Agent Warrants. The Company raised $2,500,000 in gross proceeds as part of the RDO. The Company recorded $1,705,655 as the value of common shares under common stock and $794,345 as the value of Series A Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 were $348,220. These direct costs were recorded as an offset against the statement of shareholders' equity with $238,217 being recorded under capital stock and $110,003 being recorded under additional paid-in-capital. The Company also recorded the value of the Series A Placement Agent Warrants in the amount of $52,496 as an offset against the statement of shareholders' equity with $35,816 being recorded under capital stock and $16,680 being recorded under additional paid-in-capital.
[5]	On July 7, 2020 the Company completed a public offering of its common shares or common share equivalents ("Series D Pre-Funded Warrants"), and warrants ("Series D Warrants") in a fixed combination of one common share or Series D Pre-Funded warrant, and a Series D Warrant to purchase one common share, resulting in the sale of 162,500,000 common shares, 25,000,000 Series D Pre-Funded Warrants, and Series D Warrants to purchase 187,500,000 common shares at a combined offering price of $0.16 per share for the common shares and related Series D Warrant, or a combined offering price of $0.1599 per Series D Pre-Funded Warrant and related Series D Warrant. Each Series D Pre-Funded Warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series D Warrant has an exercise price of $0.16 per share, is exercisable immediately after issuance, and has a term of 2 years. The Company raised $29,997,500 in gross proceeds as part of the public offering. The Company recorded $16,290,941 as the value of common shares under common stock, $2,329,983 as the value of the Series D Pre-Funded Warrants and $11,376,575 as the value of the Series D Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders' equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares, Series D Pre-Funded Warrants and Series D Warrants issued in July 2020 were $2,268,215. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,224,218 being recorded under capital stock and $1,043,997 being recorded under additional paid-in-capital. The Company raised $29,997,500 in gross proceeds as part of the public offering. The Company recorded $16,290,941 as the value of common shares under common stock, $2,329,983 as the value of the Series D Pre-Funded Warrants and $11,376,575 as the value of the Series D Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares, Series D Pre-Funded Warrants and Series D Warrants issued in July 2020 were $2,268,215. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,224,218 being recorded under capital stock and $1,043,997 being recorded under additional paid-in-capital.
[6]	On May 29, 2020 the Company completed a public offering of its common shares or common share equivalents ("Series C Pre-Funded Warrants"), and warrants ("Series C Warrants") in a fixed combination of one common share or Series C Pre-Funded Warrant, and a Series C Warrant to purchase one common share, resulting in the sale of 121,163,333 common shares, 12,170,000 Series C Pre-Funded Warrants, and Series C Warrants to purchase 133,333,333 common shares at a combined offering price of $0.15 per share for the common shares and related Series C Warrant, or a combined offering price of $0.1499 per Series C Pre-Funded Warrant and related Series C Warrant. Each Series C Pre-Funded Warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series C Warrant has an exercise price of $0.15 per share, is exercisable immediately after issuance and has a term of 2 years. The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the Series C Pre-Funded Warrants and $7,582,072 as the value of Series C Warrants (as disclosed in Note 13) under additional paid-in-capital in the consolidated statements of shareholders' equity using the relative fair value approach. The direct cash costs related to the issuance of the common shares, Series C Pre-Funded Warrants and Series C Warrants issued in May 2020 were $1,908,202. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,088,876 being recorded under capital stock and $819,327 being recorded under additional paid-in-capital. The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the Series C Pre-Funded Warrants and $7,582,072 as the value of Series C Warrants under additional paid-in-capital in the consolidated statements of shareholders' equity. The direct cash costs related to the issuance of the common shares, Series C Pre-Funded Warrants and Series C Warrants issued in May 2020 were $1,908,202. These direct costs were recorded as an offset against the statement of shareholders' equity with $1,088,876 being recorded under capital stock and $819,327 being recorded under additional paid-in-capital.
[7]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018.The Company recorded $465 of share issuance costs as an offset to common stock;
[8]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded $669,615 of share issuance costs as an offset to common stock in the year ended December 31, 2019.
[9]	All Series C Pre-Funded Warrants were exercised in June 2020. The cashless exercise option resulted in the issuance of 12,162,492 shares.
[10]	All Series D Pre-Funded Warrants were exercised in July 2020. The cashless exercise, option resulted in the issuance of 24,984,492 shares.
[11]	During the year ended December 31, 2020, 14,929,582 Series B Warrants have been exercised, resulting in additional cash proceeds of $2,237,437, 95,490,638 Series C Warrants have been exercised, resulting in additional cash proceeds of $14,323,596, and 48,600,625 Series D Warrants have been exercised, resulting in additional cash proceeds of $7,776,101.

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($)	Dec. 31, 2020	Oct. 20, 2020	Oct. 01, 2020	Sep. 29, 2020	Aug. 25, 2020	Jul. 09, 2020	Jun. 16, 2020	Mar. 14, 2020	Sep. 16, 2019	Aug. 19, 2019	Mar. 29, 2019	Mar. 15, 2019	Mar. 08, 2019	Jan. 10, 2019	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)											65,789	164,473	164,473		0	394,735
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	27,560,000	40,000	300,000	300,000	40,000	175,000	2,000,000	5,056,000	500,000	500,000				5,995,000	35,471,000	7,495,000
Share-based Payment Arrangement, Expense															$ 1,656,184	$ 2,539,092
Proceeds from Stock Options Exercised																600,000
Stock Issued During Period, Value, Stock Options Exercised																600,000
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised																$ (154,148)

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Issuance of Stock Options (Details) - $ / shares	Dec. 31, 2020	Dec. 24, 2020	Nov. 17, 2020	Nov. 12, 2020	Oct. 29, 2020	Oct. 20, 2020	Oct. 15, 2020	Oct. 01, 2020	Sep. 29, 2020	Sep. 25, 2020	Aug. 25, 2020	Aug. 19, 2020	Aug. 14, 2020	Aug. 02, 2020	Jul. 31, 2020	Jul. 20, 2020	Jul. 09, 2020	Jun. 16, 2020	Jun. 11, 2020	May 07, 2020	May 05, 2020	Apr. 21, 2020	Mar. 14, 2020	Mar. 01, 2020	Feb. 25, 2020	Jan. 23, 2020	Sep. 16, 2019	Aug. 19, 2019	Aug. 14, 2019	Aug. 13, 2019	Jul. 14, 2019	Jun. 16, 2019	May 23, 2019	May 04, 2019	Mar. 29, 2019	Mar. 15, 2019	Mar. 08, 2019	Feb. 24, 2019	Jan. 10, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Options, Options Outstanding (in shares)	39,604,515																																							39,604,515	7,040,265	422,044
Weighted Avg Exercise Price, Options Outstanding (in dollars per share)	$ 0.36																																							$ 0.36	$ 1.28	$ 1.95
Number of Options, Options Granted (in shares)	27,560,000					40,000		300,000	300,000		40,000						175,000	2,000,000					5,056,000				500,000	500,000											5,995,000	35,471,000	7,495,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.23					$ 0.09		$ 0.11	$ 0.11		$ 0.13						$ 0.18	$ 0.19					$ 0.19				$ 0.43	$ 0.26											$ 1.52	$ 0.23
Number of Options, Options Expired (in shares)																													(387,004)			(40,000)	(10,000)					(35,000)
Weighted Avg Exercise Price, Options Expired (in dollars per share)																													$ 2.11			$ 1.52	$ 1.52					$ 1.15
Number of Options, Options Exercised (in shares)																																			(65,789)	(164,473)	(164,473)			0	(394,735)
Weighted Avg Exercise Price, Options Exercised (in dollars per share)																																			$ 1.52	$ 1.52	$ 1.52
Number of Options, Options Cancelled (in shares)		(12,500)	(25,125)	(225,000)	(1,250)		(56,250)			(37,500)		(75,375)	(675,000)	(10,000)	(3,750)	(400,000)			(15,000)	(15,000)	(30,000)	(150,000)		(50,000)	(5,000)	(50,000)				(5,000)	(5,000)			(15,000)
Weighted Avg Exercise Price, Options Cancelled (in dollars per share)		$ 0.19	$ 0.19	$ 0.19	$ 0.19		$ 0.19			$ 0.19		$ 0.19	$ 0.19	$ 1.52	$ 0.19	$ 1.52			$ 1.52	$ 1.52	$ 1.52	$ 0.19		$ 1.52	$ 1.12	$ 1.52				$ 1.52	$ 1.52			$ 0.19
Number of Options, Options Vested (in shares)	14,624,140																																							14,624,140
Weighted Avg Exercise Price, Vested (in dollars per share)	$ 0.59																																							$ 0.59
Options 2 [Member]
Number of Options, Options Granted (in shares)																												100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)																												$ 0.35
Number of Options, Options Cancelled (in shares)			(50,000)	(950,000)										(5,000)		(50,000)
Weighted Avg Exercise Price, Options Cancelled (in dollars per share)			$ 1.52	$ 1.52										$ 0.19		$ 0.19
Options 3 [Member]
Number of Options, Options Granted (in shares)																												100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)																												$ 0.45
Options 4 [Member]
Number of Options, Options Granted (in shares)																												100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)																												$ 0.55
Option 5 [Member]
Number of Options, Options Granted (in shares)																												100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)																												$ 0.65
Option 6 [Member]
Number of Options, Options Granted (in shares)																												100,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)																												$ 0.75

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares	Dec. 31, 2020	Oct. 20, 2020	Oct. 01, 2020	Sep. 29, 2020	Aug. 25, 2020	Jul. 09, 2020	Jun. 16, 2020	Mar. 14, 2020	Sep. 16, 2019	Aug. 19, 2019	Jan. 10, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.23	$ 0.09	$ 0.11	$ 0.11	$ 0.13	$ 0.18	$ 0.19	$ 0.19	$ 0.43	$ 0.26	$ 1.52	$ 0.23
Number of Options, Options Outstanding (in shares)	39,604,515											39,604,515	7,040,265	422,044
Number of Vested Options (in shares)												14,624,140	7,040,265
Number of unvested options outstanding (in shares)	24,980,375											24,980,375
Number of Options, Options Vested (in shares)	14,624,140											14,624,140
Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)										0.35
Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)										0.45
Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)										0.55
Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)										0.65
Option 6 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)										$ 0.75
January 10, 2019 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 1.52
Number of Options, Options Outstanding (in shares)													5,540,265
Number of Vested Options (in shares)													5,540,265
Weighted Avg Remaining Life (Year)													1 year 10 days
January 10, 2019 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 1.52
Number of Options, Options Outstanding (in shares)	3,965,265											3,965,265
Number of Vested Options (in shares)												3,965,265
Weighted Avg Remaining Life (Year)												10 days
Number of unvested options outstanding (in shares)
August 16, 2019 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 0.26
Number of Options, Options Outstanding (in shares)													500,000
Number of Vested Options (in shares)													500,000
Weighted Avg Remaining Life (Year)													1 year 233 days
August 16, 2019 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 0.35
Number of Options, Options Outstanding (in shares)													100,000
Number of Vested Options (in shares)													100,000
Weighted Avg Remaining Life (Year)													1 year 233 days
August 16, 2019 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 0.45
Number of Options, Options Outstanding (in shares)													100,000
Number of Vested Options (in shares)													100,000
Weighted Avg Remaining Life (Year)													1 year 233 days
August 16, 2019 [Member] | Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 0.55
Number of Options, Options Outstanding (in shares)													100,000
Number of Vested Options (in shares)													100,000
Weighted Avg Remaining Life (Year)													1 year 233 days
August 16, 2019 [Member] | Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 0.65
Number of Options, Options Outstanding (in shares)													100,000
Number of Vested Options (in shares)													100,000
Weighted Avg Remaining Life (Year)													1 year 233 days
August 16, 2019 [Member] | Option 6 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 0.75
Number of Options, Options Outstanding (in shares)													100,000
Number of Vested Options (in shares)													100,000
Weighted Avg Remaining Life (Year)													1 year 233 days
August 19, 2019 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.26
Number of Options, Options Outstanding (in shares)	500,000											500,000
Number of Vested Options (in shares)												500,000
Weighted Avg Remaining Life (Year)												229 days
Number of unvested options outstanding (in shares)
August 19, 2019 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.35
Number of Options, Options Outstanding (in shares)	100,000											100,000
Number of Vested Options (in shares)												100,000
Weighted Avg Remaining Life (Year)												229 days
Number of unvested options outstanding (in shares)
August 19, 2019 [Member] | Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.45
Number of Options, Options Outstanding (in shares)	100,000											100,000
Number of Vested Options (in shares)												100,000
Weighted Avg Remaining Life (Year)												229 days
Number of unvested options outstanding (in shares)
August 19, 2019 [Member] | Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.55
Number of Options, Options Outstanding (in shares)	100,000											100,000
Number of Vested Options (in shares)												100,000
Weighted Avg Remaining Life (Year)												229 days
Number of unvested options outstanding (in shares)
August 19, 2019 [Member] | Option 6 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.65
Number of Options, Options Outstanding (in shares)	100,000											100,000
Number of Vested Options (in shares)												100,000
Weighted Avg Remaining Life (Year)												229 days
Number of unvested options outstanding (in shares)
August 19, 2019 [Member] | Option 7 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.75
Number of Options, Options Outstanding (in shares)	100,000											100,000
Number of Vested Options (in shares)												100,000
Weighted Avg Remaining Life (Year)												229 days
Number of unvested options outstanding (in shares)
August 19, 2019 [Member] | Option 8 [Member]
Weighted Avg Remaining Life (Year)												259 days
Number of unvested options outstanding (in shares)
August 19, 2019 [Member] | Option 9 [Member]
Weighted Avg Remaining Life (Year)												4 years 73 days
September 16, 2019 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)													$ 0.43
Number of Options, Options Outstanding (in shares)													500,000
Number of Vested Options (in shares)													500,000
Weighted Avg Remaining Life (Year)													1 year 259 days
September 16, 2019 [Member] | Option 8 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.43
Number of Options, Options Outstanding (in shares)	500,000											500,000
Number of Vested Options (in shares)												500,000
March 14, 2020 [Member] | Option 9 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.19
Number of Options, Options Outstanding (in shares)	3,724,250											3,724,250
Number of unvested options outstanding (in shares)	2,779,125											2,779,125
Number of Options, Options Vested (in shares)	945,125											945,125
June 16, 2020 [Member] | Option 10 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.19
Number of Options, Options Outstanding (in shares)	2,000,000											2,000,000
Weighted Avg Remaining Life (Year)												4 years 167 days
Number of unvested options outstanding (in shares)
Number of Options, Options Vested (in shares)	2,000,000											2,000,000
July 9, 2020 [Member] | Option 11 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.18
Number of Options, Options Outstanding (in shares)	175,000											175,000
Weighted Avg Remaining Life (Year)												4 years 189 days
Number of unvested options outstanding (in shares)	131,250											131,250
Number of Options, Options Vested (in shares)	43,750											43,750
August 25, 2020 [Member] | Option 12 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.13
Number of Options, Options Outstanding (in shares)	40,000											40,000
Weighted Avg Remaining Life (Year)												4 years 237 days
Number of unvested options outstanding (in shares)	30,000											30,000
Number of Options, Options Vested (in shares)	10,000											10,000
September 29, 2020 [Member] | Option 13 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.11
Number of Options, Options Outstanding (in shares)	300,000											300,000
Weighted Avg Remaining Life (Year)												4 years 273 days
Number of unvested options outstanding (in shares)	225,000											225,000
Number of Options, Options Vested (in shares)	75,000											75,000
October 1, 2020 [Member] | Option 14 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.11
Number of Options, Options Outstanding (in shares)	300,000											300,000
Weighted Avg Remaining Life (Year)												4 years 273 days
Number of unvested options outstanding (in shares)	225,000											225,000
Number of Options, Options Vested (in shares)	75,000											75,000
October 20, 2020 [Member] | Option 15 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)												$ 0.09
Number of Options, Options Outstanding (in shares)	40,000											40,000
Weighted Avg Remaining Life (Year)												4 years 295 days
Number of unvested options outstanding (in shares)	30,000											30,000
Number of Options, Options Vested (in shares)	10,000											10,000
December 31, 2020 [Member] | Option 16 [Member]
Number of Options, Options Outstanding (in shares)	27,560,000											27,560,000
Weighted Avg Remaining Life (Year)												10 years
Number of unvested options outstanding (in shares)	21,560,000											21,560,000
Number of Options, Options Vested (in shares)	6,000,000											6,000,000

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	Dec. 31, 2020	Oct. 20, 2020	Oct. 01, 2020	Sep. 29, 2020	Aug. 25, 2020	Jul. 09, 2020	Jun. 16, 2020	Mar. 14, 2020	Sep. 16, 2019	Aug. 19, 2019	Jan. 10, 2019
Volatility	102.00%	100.00%	100.00%	100.00%	99.00%	100.00%	100.00%	87.00%	89.00%	87.00%	68.00%
Risk-free interest rate	0.51%	0.34%	0.27%	0.24%	0.30%	0.28%	0.21%	0.49%	1.74%	1.48%	2.56%
Expected life (years) (Year)	5 years 273 days	5 years	5 years	5 years	5 years	5 years	5 years	5 years	2 years	2 years	2 years
Divedend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common share price (in dollars per share)	$ 0.23	$ 0.08	$ 0.10	$ 0.10	$ 0.13	$ 0.17	$ 0.19	$ 0.18	$ 0.42	$ 0.26	$ 1.23
Strike price (in dollars per share)	$ 0.23	$ 0.09	$ 0.11	$ 0.11	$ 0.13	$ 0.18	$ 0.19	$ 0.19	$ 0.43		$ 1.52
Minimum [Member]
Strike price (in dollars per share)										0.26
Maximum [Member]
Strike price (in dollars per share)										$ 0.75

Note 13 - Warrants (Details Tex

Note 13 - Warrants (Details Textual) - $ / shares	Jul. 07, 2020	May 29, 2020	Apr. 09, 2020	Feb. 14, 2020
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Warrants and Rights Outstanding, Term (Year)				5 years 182 days
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,666,667	1,041,667
Warrants and Rights Outstanding, Term (Year)			5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15	$ 0.15
Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		133,333,333
Warrants and Rights Outstanding, Term (Year)		2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15
Series C Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		12,170,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Series D Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	187,500,000
Warrants and Rights Outstanding, Term (Year)	2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.16
Series D Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	25,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001

Note 13 - Warrants - Details of

Note 13 - Warrants - Details of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Warrant Issued (in shares)	202,020,823
Warrant One [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.20
Warrant Issued (in shares)	20,833,334
Warrants, weighted average remaining life (Year)	4 years 226 days
Warrant Two [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrant Issued (in shares)	1,041,667
Warrants, weighted average remaining life (Year)	4 years 43 days
Warrant Three [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrant Issued (in shares)	3,403,752
Warrants, weighted average remaining life (Year)	4 years 98 days
Warrant Four [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrant Issued (in shares)	37,842,695
Warrants, weighted average remaining life (Year)	1 year 149 days
Warrant Five [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.16
Warrant Issued (in shares)	138,899,375
Warrants, weighted average remaining life (Year)	1 year 189 days

Note 13 - Warrants - Assumption

Note 13 - Warrants - Assumptions Used to Value Warrants at Grant Date (Details)	Jul. 07, 2020	May 29, 2020	Apr. 09, 2020	Feb. 14, 2020
Measurement Input, Price Volatility [Member] | Series A Warrants [Member]
Fair value assumptions				0.87
Measurement Input, Price Volatility [Member] | Placement Agent Warrants Issued With Series A Warrants [Member]
Fair value assumptions				0.87
Measurement Input, Price Volatility [Member] | Series B Warrant [Member]
Fair value assumptions			0.99
Measurement Input, Price Volatility [Member] | Placement Agent Warrants Issued With Series B Warrants [Member]
Fair value assumptions			0.99
Measurement Input, Price Volatility [Member] | Series C Warrants [Member]
Fair value assumptions		1.18
Measurement Input, Price Volatility [Member] | Series D Warrant [Member]
Fair value assumptions	1.18
Measurement Input, Risk Free Interest Rate [Member] | Series A Warrants [Member]
Fair value assumptions				0.0142
Measurement Input, Risk Free Interest Rate [Member] | Placement Agent Warrants Issued With Series A Warrants [Member]
Fair value assumptions				0.0142
Measurement Input, Risk Free Interest Rate [Member] | Series B Warrant [Member]
Fair value assumptions			0.0041
Measurement Input, Risk Free Interest Rate [Member] | Placement Agent Warrants Issued With Series B Warrants [Member]
Fair value assumptions			0.0041
Measurement Input, Risk Free Interest Rate [Member] | Series C Warrants [Member]
Fair value assumptions		0.0016
Measurement Input, Risk Free Interest Rate [Member] | Series D Warrant [Member]
Fair value assumptions	0.0016
Measurement Input, Expected Term [Member] | Series A Warrants [Member]
Fair value assumptions				5.5
Measurement Input, Expected Term [Member] | Placement Agent Warrants Issued With Series A Warrants [Member]
Fair value assumptions				5
Measurement Input, Expected Term [Member] | Series B Warrant [Member]
Fair value assumptions			5
Measurement Input, Expected Term [Member] | Placement Agent Warrants Issued With Series B Warrants [Member]
Fair value assumptions			5
Measurement Input, Expected Term [Member] | Series C Warrants [Member]
Fair value assumptions		2
Measurement Input, Expected Term [Member] | Series D Warrant [Member]
Fair value assumptions	2
Measurement Input, Expected Dividend Rate [Member] | Series A Warrants [Member]
Fair value assumptions				0
Measurement Input, Expected Dividend Rate [Member] | Placement Agent Warrants Issued With Series A Warrants [Member]
Fair value assumptions				0
Measurement Input, Expected Dividend Rate [Member] | Series B Warrant [Member]
Fair value assumptions			0
Measurement Input, Expected Dividend Rate [Member] | Placement Agent Warrants Issued With Series B Warrants [Member]
Fair value assumptions			0
Measurement Input, Expected Dividend Rate [Member] | Series C Warrants [Member]
Fair value assumptions		0
Measurement Input, Expected Dividend Rate [Member] | Series D Warrant [Member]
Fair value assumptions	0
Measurement Input, Offered Price [Member] | Series A Warrants [Member]
Fair value assumptions				0.12
Measurement Input, Offered Price [Member] | Placement Agent Warrants Issued With Series A Warrants [Member]
Fair value assumptions				0.12
Measurement Input, Offered Price [Member] | Series B Warrant [Member]
Fair value assumptions			0.14
Measurement Input, Offered Price [Member] | Placement Agent Warrants Issued With Series B Warrants [Member]
Fair value assumptions			0.14
Measurement Input, Offered Price [Member] | Series C Warrants [Member]
Fair value assumptions		0.16
Measurement Input, Offered Price [Member] | Series D Warrant [Member]
Fair value assumptions	0.17
Measurement Input, Exercise Price [Member] | Series A Warrants [Member]
Fair value assumptions				0.2
Measurement Input, Exercise Price [Member] | Placement Agent Warrants Issued With Series A Warrants [Member]
Fair value assumptions				0.15
Measurement Input, Exercise Price [Member] | Series B Warrant [Member]
Fair value assumptions			0.15
Measurement Input, Exercise Price [Member] | Placement Agent Warrants Issued With Series B Warrants [Member]
Fair value assumptions			0.15
Measurement Input, Exercise Price [Member] | Series C Warrants [Member]
Fair value assumptions		0.15
Measurement Input, Exercise Price [Member] | Series D Warrant [Member]
Fair value assumptions	0.16

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Combined Federal and Provincial Statutory Income Tax Rate, Percent	27.00%	27.00%

Note 14 - Income Taxes - Effect

Note 14 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Loss before income taxes	$ (16,911,784)	$ (19,784,054)
Expected income tax expense (recovery)	(4,058,828)	(5,341,690)
Difference in foreign tax rates	(74,847)	54,660
Tax rate changes and other adjustments	1,540,539
Stock based compensation and non-deductible expenses	407,689	771,640
Foreign accrual property income	210,605	261,160
Prior period adjustment	32,518
Share issuance costs recorded in equity	(1,282,179)	(198,930)
Change in valuation allowance	3,224,503	4,453,160
Total income tax expense

Note 14 - Income Taxes - Deferr

Note 14 - Income Taxes - Deferred Taxes (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Intangible assets - licenses	$ 4,236,169	$ 3,622,890
Share issuance costs	1,148,179	301,180
Reserves	28,784	20,410
Non-capital losses carried forward - Canada	6,182,002	5,498,910
Operating leases	345,937	6,560
Other	466	350
Total deferred tax assets	17,060,027	13,632,310
Property and equipment	(94,218)	(231,240)
Right-of-use asset	(340,242)
Total deferred tax liabilities	(434,460)	(231,240)
Valuation allowance	16,625,567	13,401,070
Net deferred tax asset
Canada Revenue Agency [Member]
Net operating losses carried forward - US	5,091,162	4,154,520
Internal Revenue Service (IRS) [Member]
Investment Tax Credits	$ 27,328	$ 27,330

Note 14 - Income Taxes - Non-ca

Note 14 - Income Taxes - Non-capital and Non-operating Loss Carryforwards (Details)	Dec. 31, 2020USD ($)
Canada Revenue Agency [Member] | Foreign Tax Authority [Member]
Non-operating loss carryforward	$ 27,755,766
Canada Revenue Agency [Member] | Foreign Tax Authority [Member] | Tax Year 2036 [Member]
2036	3,763,071
Canada Revenue Agency [Member] | Foreign Tax Authority [Member] | Tax Year 2037 [Member]
2036	4,278,944
Canada Revenue Agency [Member] | Foreign Tax Authority [Member] | Tax Year 2038 [Member]
2036	5,416,916
Canada Revenue Agency [Member] | Foreign Tax Authority [Member] | Tax Year 2039 [Member]
2036	6,773,728
Canada Revenue Agency [Member] | Foreign Tax Authority [Member] | Tax Year 2040 [Member]
2036	7,523,107
Internal Revenue Service (IRS) [Member] | Domestic Tax Authority [Member]
2036	19,595,073
Internal Revenue Service (IRS) [Member] | Domestic Tax Authority [Member] | Tax Year 2036 [Member]
2036	1,484,636
Internal Revenue Service (IRS) [Member] | Domestic Tax Authority [Member] | Tax Year 2035 [Member]
2036	856,301
Internal Revenue Service (IRS) [Member] | Domestic Tax Authority [Member] | Tax Year 2037 [Member]
2036	3,831,764
Internal Revenue Service (IRS) [Member] | Domestic Tax Authority [Member] | Indefinitely [Member]
2036	$ 13,422,372

Note 15 - Commitments and Con_2

Note 15 - Commitments and Contingencies (Details Textual) - USD ($)	Feb. 19, 2020	Sep. 12, 2019	May 10, 2018
Qorvo Biotechnologies, LLC [Member]
Development and Supply Agreement, Contingent on Achievement of Future Milestone, First Payment, Cash Only		$ 3,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, First Payment, Cash Portion		1,500,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, First Payment, Equity Portion		1,950,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Cash Only	$ 2,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Third Payment, Cash Only		3,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Third Payment, Cash Portion		1,500,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Third Payment, Equity Portion		$ 1,950,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Fourth Payment, Cash Only	$ 2,000,000
Seraph Biosciences, Inc. [Member]
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash			$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity			$ 3,500,000

Note 16 - Financial Instrumen_3

Note 16 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accounts payable and Accrued Liabilities, maturity less than 3 Months	$ 1,248,628	$ 2,087,525
Accounts payable and accrued liabilities, Maturity 3 to 6 Months
Accounts payable and accrued liabilities, Maturity 6 to 9 Months
Accounts payable and accrued liabilities, Maturity 9 to 12 Months
Accounts payable and accrued liabilities
Accounts payable and accrued liabilities	1,248,628	2,087,525
Debt obligations, maturity less than 3 Months	527,360
Debt obligations, Maturity 3 to 6 Months
Debt obligations, Maturity 6 to 9 Months
Debt obligations, Maturity 9 to 12 Months
Debt obligations, Maturity Greater Than 1 Year
Long-term Debt, Total	527,360
Lease obligations, maturity less than 3 Months	59,662
Lease obligations, Maturity 3 to 6 Months	62,463
Lease obligations, Maturity 6 to 9 Months	64,356
Lease obligations, Maturity 9 to 12 Months	66,307
Long term portion of lease liabilities	1,087,998
Total lease liabilities at December 31, 2020	1,340,786
Maturity Less Than 3 Months	1,835,650	2,087,525
Maturity 3 to 6 Months	62,463
Maturity 6 to 9 Months	64,356
Maturity 9 to 12 Months	66,307
Maturity Greater Than 1 Year	1,087,998
Liabilities, Total	$ 3,116,774	$ 2,087,525

Note 17 - Segmented Informati_3

Note 17 - Segmented Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Assets	$ 66,144,034	$ 4,182,984
Total US property and equipment	583,007	729,142
Total US right-of-use asset	1,318,716	1,103,658
Property, Plant and Equipment, Including Leased Assets	1,901,723	1,832,800
CANADA
Assets	53,160,701	249,929
UNITED STATES
Assets	12,983,333	3,933,055
Total US property and equipment	$ 583,007	$ 729,142

Note 18 - Schedule of Expense_2

Note 18 - Schedule of Expenses - Schedule of Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Research and development	$ 8,043,891	$ 10,345,291
Professional fees	2,179,082	1,666,089
General and administrative	6,011,985	6,985,334
Salaries, Bonus and Benefits [Member]
Research and development	557,634	880,818
Professional fees
General and administrative	4,336,545	5,581,358
Contracted Expenditures [Member]
Research and development	2,064,597	2,843,998
Professional fees
General and administrative
Marketing and Investor Relations [Member]
Research and development		2,303
Professional fees
General and administrative	261,911	471,887
Travel and Accommodation [Member]
Research and development	534	37,181
Professional fees
General and administrative	16,691	435,530
Insurance [Member]
Research and development	982	5,653
Professional fees
General and administrative	231,005	125,888
License Fees [Member]
Research and development	5,000,000	5,936,841
Professional fees
General and administrative
Office [Member]
Research and development	43,918	50,599
Professional fees
General and administrative	435,415	197,815
Consultant [Member]
Research and development	107,029	251,096
Professional fees	2,179,082	1,666,089
General and administrative
Regulatory [Member]
Research and development	151,073	127,190
Professional fees
General and administrative	430,471	106,230
Amortization, Right-of-use Asset [Member]
Research and development	83,425
Professional fees
General and administrative	299,947	32,473
Supplies [Member]
Research and development	34,699	209,612
Professional fees
General and administrative		$ 34,153

Note 20 - Loss Per Share (Detai

Note 20 - Loss Per Share (Details Textual) - shares	12 Months Ended
	Dec. 21, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	39,604,515	7,040,265
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	202,020,823

Note 20 - Loss Per Share - Loss

Note 20 - Loss Per Share - Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net loss for the year	$ 16,911,784	$ 19,784,054
Weighted average shares - basic (in shares)	364,444,664	106,297,975
Warrants (in shares)
Stock options (in shares)
Denominator for diluted loss per share (in shares)	364,444,664	106,297,975
Loss per share - basic and diluted (in dollars per share)	$ (0.05)	$ (0.19)

Note 21 - Related Party Trans_3

Note 21 - Related Party Transactions and Key Management Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction, Amounts of Transaction	$ 0
Gerald Solensky, Jr. [Member]
Related Party Transaction, Amounts of Transaction		$ 169,143

Note 21 - Related Party Trans_4

Note 21 - Related Party Transactions and Key Management Compensation - Key Management Personnel Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation	$ 1,656,184	$ 2,539,092
Director and Executive Officers [Member]
Salaries and benefits, including bonuses	1,010,943	1,463,830
Stock-based compensation	1,548,747	1,842,313
Total	$ 2,559,690	$ 3,306,143

Note 23 - Subsequent Events (De

Note 23 - Subsequent Events (Details Textual) - USD ($)	Feb. 16, 2021	Feb. 11, 2021	Feb. 08, 2021	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Issuance of Common Stock				$ 56,496,283	$ 3,000,000
Subsequent Event [Member] | Upsized Firm Commitment Offering [Member]
Equity Offering, Shares Committed (in shares)			91,315,790
Shares Issued, Price Per Share (in dollars per share)	$ 1.90		$ 1.90
Option to Purchase Additional Shares, Period (Day)			30 days
Common Stock, Additional Shares Authorized (in shares)			13,697,368
Proceeds from Issuance of Common Stock	$ 26,000,000	$ 173,500,000
Stock Issued During Period, Shares, New Issues (in shares)	13,697,368